Isobenzofuran-1 (3H)-ketone compound as well as preparation method, pharmaceutical composition and application thereof
By designing a new structure of isobenzofuran-1(3H)-one compounds, the liver toxicity and adverse reaction problems of existing MAO-B inhibitors are solved, and effective inhibition of MAO-B and MAO-A is provided. Expand the drug selection for the treatment of diseases such as Parkinson, and improve the safety and effectiveness of the treatment.
Patent Information
- Application Number
- CN202310527548.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-11
- Publication Date
- 2024-11-12
AI Technical Summary
Existing MAO-B selective inhibitors have hepatic toxicity and other adverse reactions in the treatment of neuropsychiatric diseases such as Parkinson, and the lack of new structural types of reversible inhibitors limits the effectiveness and safety of the treatment.
A new class of isobenzofuran-1(3H)-one compounds and their salts were designed as inhibitors of MAO-B and MAO-A, prepared by specific synthetic methods, and used as potential drug basis To treat diseases related to MAO-B and MAO-A.
This compound has a significant inhibitory activity on MAO-B and also has an inhibitory effect on MAO-A, providing new drug choices for the treatment of neuropsychiatric diseases, metabolic diseases, cardiovascular system diseases and cancer, improving the safety of treatment Sex and effectiveness.
Smart Images

Figure CN118930552A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology and relates to isobenzofuran-1(3H)-one compounds of a novel structure as shown in formula I, pharmaceutically acceptable salts thereof and a preparation method thereof, a composition containing one or more such compounds, and uses of such compounds in inhibiting monoamine oxidase B / A (MAO-B / A) and treating diseases related to MAO-B / A, and in preparing, preventing and / or treating drugs for neuropsychiatric diseases, cardiovascular diseases, metabolic diseases or cancer. Background Art
[0002] Monoamine oxidase (MAOs) is a flavin enzyme with flavin adenine dinucleotide FAD as a coenzyme. It is located on the outer membrane of mitochondria and can catalyze the oxidative deamination reaction of endogenous (neurotransmitters) and exogenous monoamines [Advances in Experimental Medicine and Biology, 1982, 148: 141-153]. Studies have shown that MAOs play an important role in the central and peripheral nervous systems (CNS and PNS) by regulating the levels of monoamine neurotransmitters [Med Res Rev. 2019; 39: 1603-1706]. MAOs include two subtypes, MAO-A and MAO-B, both of which are distributed in most tissues of mammals and can participate in the metabolism of monoamine neurotransmitters, but they have certain differences in tissue cell distribution, substrate selectivity, and inhibitor sensitivity [Prog Nucleic Acid Res Mol Biol. 2001; 65: 129-56]. In terms of tissue distribution, MAO-A and MAO-B are distributed in different areas of the brain. MAO-A is mainly located in neurons in catecholamine-rich areas, including the substantia nigra, locus coeruleus, subcoeruleus nucleus and periventricular area of the hypothalamus, while MAO-B is mainly located in serotonergic neurons and astrocytes, including the dorsal raphe nucleus and supracentral nucleus [Neuroscience. 1988 May; 25(2): 439-56]. In terms of substrate specificity, MAO-A has a higher affinity for 5-hydroxytryptamine (5-HT), while MAO-B has a higher affinity for benzylamine (BA) and phenylethylamine (PEA). Catecholamines such as dopamine (DA), epinephrine (E), noradrenaline (NE) and tyramine are common substrates of both MAOA and MAOB subtypes [British Journal of Pharmacology (2006) 147, S287–S296]. These monoamine substrates can be oxidized and deaminated to generate aldehydes, ammonia and hydrogen peroxide under the action of MAO-A and / or MAO-B. Reactive oxygen species (ROS) related to hydrogen peroxide play an important role in degenerative diseases and chronic diseases related to aging [Chem Res Toxicol, 2008, 21(1): 172-188].
[0003] Studies have shown that the main pathological changes of Parkinson's disease are the significant loss of dopaminergic neurons in the substantia nigra and the significant decrease in dopamine content in the striatum. In addition, the activity of MAO-B in the substantia nigra of Parkinson's patients is significantly enhanced. Therefore, inhibiting the activity of MAO-B can reduce the metabolism of dopamine, increase the dopamine content in the patient's brain, improve Parkinson's symptoms, and at the same time reduce the reactive oxygen species produced by the oxidation reaction catalyzed by MAO-B that damage cells, and has a potential neuroprotective effect [Advanced drug delivery reviews, 2008, 60 (13-14): 1527-1533]. MAO-B inhibitors can be used to treat neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. At present, selective MAO-B inhibitors have become one of the strategies for treating various neurodegenerative diseases such as Parkinson's disease, and can also be used to treat diseases such as depression and anxiety.
[0004] So far, three structural types of MAO-B selective inhibitors have been approved for the treatment of neurological or psychiatric diseases [Current Medicinal Chemistry, 2004, 11 (15): 2033-2043]. These include the irreversible MAO-B inhibitors selegiline and rasagiline, which can be used alone to treat early Parkinson's disease (PD) or in combination with levodopa to treat mid- to late-stage PD [Neuropsychopharmacology (2015) 40, 650–657; Molecular Neurodegeneration 2007, 2: 13]. The reversible MAO-B inhibitor safinamide (SAF) is approved for use in combination with levodopa or DA agonists to treat motor complications in patients with mid- to late-stage or early-stage PD, respectively [Drugs. 2015Apr; 75 (6): 705-11]. However, irreversible MAO inhibitors may cause adverse reactions such as liver toxicity and hypertension, while reversible inhibitors are potentially safe and effective therapeutic drugs [Journal of Medicinal Chemistry, 2004, 47(7): 1760-1766]. Therefore, finding new structural types of MAO-B reversible inhibitors has important clinical application value and is an important way to obtain new drugs for the treatment of neuropsychiatric diseases such as Parkinson's disease.
[0005] Inhibiting the activity of MAO-A and / or MAO-B is an important strategy and means for treating mental and nervous system diseases, including depression, anxiety, Parkinson's disease, Alzheimer's disease, epilepsy and other diseases; it is also a potential treatment for metabolic diseases such as obesity; cardiovascular diseases such as chronic obstructive pulmonary disease, pulmonary hypertension, heart failure, etc.; or cancer [Ageing Research Reviews, 2021, 66, 101256]. Therefore, new structural MAO-A and MAO-B inhibitors have important clinical significance, especially selective MAO-B inhibitors for the treatment of Parkinson's disease, which have been used in clinical practice.
[0006] This patent designs and synthesizes a new structure of isobenzofuran-1(3H)-one compounds, which have stronger or equivalent inhibitory activity on MAO-B than MAO-A, providing a new material basis for the treatment of diseases related to MAO-B and / or MAO-A. Summary of the invention
[0007] The technical problem solved by the present invention is to provide isobenzofuran-1(3H)-one compounds and physiologically acceptable salts shown in formula I, their preparation methods, pharmaceutical compositions, and their use in preparing MAO-B and / or MAO-A inhibitors and potential drugs thereof, and in preparing drugs for treating neuropsychiatric diseases, metabolic diseases, cardiovascular diseases or cancer.
[0008] In order to solve the technical problem of the present invention, the present invention provides the following technical solutions:
[0009] The first aspect of the technical solution of the present invention is to provide an isobenzofuran-1(3H)-one derivative or a physiologically acceptable salt thereof as shown in the general formula I:
[0010]
[0011] In Formula I,
[0012] A is selected from: NH, O;
[0013] R1 is selected from:
[0014] (1) C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched alkyl;
[0015] (2) Substituted or unsubstituted C3, C4, C5, C6, C7 cycloalkanes, substituted or unsubstituted C3, C4, C5, C6, C7 cycloalkanes substituted with methyl, including but not limited to the following structures:
[0016]
[0017] wherein X is selected from CH2, NH, O, S; R4 is selected from C1, C2, C3 straight chain or branched alkyl, halogen-substituted C1, C2, C3 straight chain or branched alkyl; halogen is selected from F, Cl;
[0018] R2 and R3 are independently selected from H, C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, nitro-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, (CH2)nORw1, CH2CH(CH3)CH2ORw1, (CH2)mCHCH3ORw1, CH2C(CH3)2ORw1, CH2CH(CH2CH3)ORw1, (CH2)nNRw2Rw3, CH2CH(CH3)CH2NRw2Rw3, (CH2)mCH(CH3)NRw2Rw3, CH2C(CH3)2NRw2Rw3, CH2CH(CH2CH3)NRw2Rw3, Wherein said Rw1, Rw2, Rw3 are independently selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen substituted C1, C2, C3, C4 straight chain or branched alkyl; n is selected from 0, 1, 2, 3, 4; m is selected from 0, 1, 2; o is selected from 1, 2, 3, 4, 5; X is selected from CH2, NH, O. The second aspect of the technical solution of the present invention is to provide isobenzofuran-1 (3H) -one derivatives or physiologically acceptable furan salts as shown in the general formula IA:
[0019]
[0020] In Formula IA,
[0021] R1 is selected from:
[0022] (1) C1, C2, C3, C4, C5, C6 straight chain or branched chain alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched chain alkyl;
[0023] (2) Substituted or unsubstituted C3, C4, C5, C6, C7 cyclic alkanes, including but not limited to the following structures:
[0024]
[0025] Wherein X is selected from CH2, NH, O, S; R4 is selected from C1, C2, C3 straight chain or branched alkyl, halogen-substituted C1, C2, C3 straight chain or branched alkyl; halogen is selected from F, Cl.
[0026] The third aspect of the technical solution of the present invention is to provide isobenzofuran-1(3H)-one derivatives or physiologically acceptable salts thereof as shown in the general formula IB:
[0027]
[0028] In Formula IB,
[0029] R1 is selected from:
[0030] (1) C1, C2, C3, C4, C5, C6 straight chain or branched chain alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched chain alkyl;
[0031] (2) Substituted or unsubstituted C3, C4, C5, C6, C7 cyclic alkanes, including but not limited to the following structures:
[0032]
[0033] wherein X is selected from CH2, NH, O, S; R4 is selected from C1, C2, C3 straight chain or branched alkyl, halogen-substituted C1, C2, C3 straight chain or branched alkyl; halogen is selected from F, Cl;
[0034] R5 is selected from the group consisting of C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, nitro-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, (CH2)nORw1, CH2CH(CH3)CH2ORw1, (CH2)mCHCH3ORw1, CH2C(CH3)2ORw1, CH2CH(CH2CH3)ORw1, (CH2)nNRw2Rw3, CH2CH(CH3)CH2NRw2Rw3, (CH2)mCH(CH3)NRw2Rw3, CH2C(CH3)2NRw2Rw3, CH2CH(CH2CH3)NRw2Rw3, Wherein Rw1, Rw2, and Rw3 are independently selected from C1, C2, C3, and C4 straight chain or branched alkyl, and halogen-substituted C1, C2, C3, and C4 straight chain or branched alkyl; n is selected from 0, 1, 2, 3, and 4; m is selected from 0, 1, and 2; o is selected from 1, 2, 3, 4, and 5; and X is selected from CH2, NH, and O.
[0035] The fourth aspect of the technical solution of the present invention is to provide isobenzofuran-1(3H)-one derivatives or physiologically acceptable salts thereof as shown in the general formula IC:
[0036]
[0037] In the IC,
[0038] R1 is selected from:
[0039] (1) C1, C2, C3, C4, C5, C6 straight chain or branched chain alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched chain alkyl;
[0040] (2) Substituted or unsubstituted C3, C4, C5, C6, C7 cyclic alkanes, including but not limited to the following structures:
[0041]
[0042] wherein X is selected from CH2, NH, O, S; R4 is selected from C1, C2, C3 straight chain or branched alkyl, halogen-substituted C1, C2, C3 straight chain or branched alkyl; halogen is selected from F, Cl;
[0043] R6 is selected from the group consisting of C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, nitro-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, (CH2)nORw1, CH2CH(CH3)CH2ORw1, (CH2)mCHCH3ORw1, CH2C(CH3)2ORw1, CH2CH(CH2CH3)ORw1, (CH2)nNRw2Rw3, CH2CH(CH3)CH2NRw2Rw3, (CH2)mCH(CH3)NRw2Rw3, CH2C(CH3)2NRw2Rw3, CH2CH(CH2CH3)NRw2Rw3, Wherein Rw1, Rw2, and Rw3 are independently selected from C1, C2, C3, and C4 straight chain or branched alkyl, and halogen-substituted C1, C2, C3, and C4 straight chain or branched alkyl; n is selected from 0, 1, 2, 3, and 4; m is selected from 0, 1, and 2; o is selected from 1, 2, 3, 4, and 5; and X is selected from CH2, NH, and O.
[0044] In the fifth aspect of the technical solution of the present invention, in order to achieve the purpose of the present invention, preferred compounds include but are not limited to:
[0045]
[0046]
[0047] The sixth aspect of the technical solution of the present invention is to provide a method for preparing the compound described in the first to fifth aspects, and the technical solution adopted comprises the following steps:
[0048] According to the structure of the 3-substituent (R2, R3), the compound of general formula I was synthesized using the synthesis method of Scheme 1-5;
[0049] Using 1,2,3,4-tetrahydroisoquinolin-6-ol 1 as the starting material, a trifluoroacetyl protecting group was introduced at the 1-position of 1,2,3,4-tetrahydroisoquinolin-6-ol through an acylation reaction to obtain intermediate 2;
[0050] Intermediate 2 is acylated with trifluoromethanesulfonyl chloride to prepare intermediate 3;
[0051] Intermediate 3 is reacted with N-formyl saccharin through coupling reaction to prepare intermediate 4;
[0052] Intermediate 4 undergoes bromination reaction with NBS to obtain intermediate 5;
[0053] Intermediate 5 was treated with potassium carbonate aqueous solution to remove the trifluoroacetyl group to obtain a non-substituted compound on the N side; on this basis, an acylation reaction was used to introduce a Boc substituent to obtain intermediate 6;
[0054] Intermediate 6 is reduced to give intermediate 7;
[0055] Intermediate 7 undergoes carbonyl insertion coupling reaction to obtain a compound of formula IA;
[0056] If the substituted N atom is a Boc group, a 1,4-dioxane solution of trifluoroacetic acid or hydrogen chloride is used to remove the Boc group to obtain a compound without substitution on N; on this basis, a substituent R1 is introduced through a substitution reaction to obtain a compound represented by the general formula IA;
[0057] Using 1,2,3,4-tetrahydroisoquinolin-6-ol 1 as the starting material, a Boc protecting group was introduced at the 1-position of 1,2,3,4-tetrahydroisoquinolin-6-ol through an acylation reaction to obtain intermediate 8;
[0058] Intermediate 8 undergoes Friedel-Crafts acylation with paraformaldehyde to prepare intermediate 9;
[0059] Intermediate 9 is acylated with trifluoromethanesulfonyl chloride to prepare intermediate 10;
[0060] Intermediate 10 undergoes Pinnick oxidation reaction to obtain intermediate 11;
[0061] Intermediate 11 undergoes esterification reaction with methyl iodide to obtain intermediate 12;
[0062] Intermediate 12 undergoes coupling reaction with potassium vinyl trifluoroborate to obtain intermediate 13;
[0063] Intermediate 13 is subjected to oxidation reaction to obtain intermediate 14;
[0064] Intermediate 14 undergoes an addition reaction with an alkyl Grignard reagent to introduce R5 to obtain a compound represented by the general formula IB;
[0065] If the substituted N atom is a Boc group, a 1,4-dioxane solution of trifluoroacetic acid or hydrogen chloride is used to remove the Boc group, and on this basis, a substituent is introduced through a substitution reaction to obtain a compound represented by the general formula IB.
[0066] Intermediate 13 undergoes hydrolysis to obtain intermediate 15;
[0067] Intermediate 15 is subjected to oxidation reaction to obtain intermediate 16;
[0068] Intermediate 16 undergoes substitution reaction with an alkyl halide to give intermediate 17;
[0069] Intermediate 17 is treated with a 1,4-dioxane solution of trifluoroacetic acid or hydrogen chloride to remove Boc, and a substituent is introduced through a substitution reaction to obtain a compound of the general formula IB;
[0070] Intermediate 10 reacts with substituted acetylene compounds via Sonogashira coupling to prepare key intermediate 18;
[0071] Intermediate 18 undergoes Pinnick oxidation reaction to obtain intermediate 19;
[0072] Intermediate 19 undergoes hydrogenation reduction reaction to obtain intermediate 20;
[0073] Intermediate 20 uses trifluoroacetic acid or hydrogen chloride in 1,4-dioxane solution to remove Boc, and introduces a substituent through a substitution reaction to obtain a compound represented by the general formula IB;
[0074] Intermediate 10 was reacted with triisopropylsilyl acetylene via Sonogashira coupling to prepare key intermediate 21;
[0075] The silicon protecting group of intermediate 21 was removed by tetrabutylammonium fluoride to obtain intermediate 22;
[0076] Intermediate 22 undergoes Pinnick oxidation reaction to obtain intermediate 23;
[0077] Intermediate 23 undergoes hydrolysis to obtain intermediate 24;
[0078] Intermediate 24 undergoes esterification with methyl iodide to give intermediate 25;
[0079] Intermediate 25 undergoes a nucleophilic addition reaction with an alkyl Grignard reagent or DAST to obtain a compound represented by the general formula IC; if the substituted N atom is a Boc group, a 1,4-dioxane solution of trifluoroacetic acid or hydrogen chloride is used to remove the Boc group to obtain a compound without substitution on N; on this basis, a substituent is introduced through a substitution reaction to obtain a compound represented by the general formula IC;
[0080] The preferred preparation methods and conditions of the compounds represented by the general formula IA, IB, and IC are shown in Schemes 1, 2, 3, 4, and 5;
[0081] Scheme 1
[0082]
[0083] Scheme 1.Reagents and conditions: (i) (COCF3)2O,TEA,rt; (ii)TfCl,TEA,0℃; (iii)N-forMylsaccharin,Pd(OAc)2,DPPF,Et3SiH,MeCN ;(iv)4-chloro-2-(trifluoromethyl)aniline,NBS,Pd(OAc)2,DCE:CF3COOH=5:1,60℃;(v)1)aqueousPotassium Carbonate,MeOH; 2) Boc2O; (vi) NaBH4, MeOH; (vii) 1) Co2(CO)8, Pd(OAc)2, DPPF, DMAP, 1,4-dioxane, 90℃, microwave; 2) CF3COOH, NH3 H2O; 3) R1OCOCl, TEA.
[0084]
[0085] Scheme 2.Reagents and conditions: (i) Boc2O,TEA,rt; (ii) (CH2O) n,MgCl2,TEA,90℃;(iii)TfCl,TEA,0℃;(iv)NaClO2,NaH2PO4,2-Methyl-1-butene,r.t;(v)CH3I,KHCO3,60℃;(vi)Potassium ethenyltrifluoroborate,PdCl2(dppf)CH2Cl2,TEA,60℃;(vii)Sodium periodate,Potassium osmate(VI)dihydrate,-20℃-0℃;(viii)1)R5MgBr,THF,0℃;2)CF3CO OH,DCM,0℃;3)R1OCOCl,TEA.
[0086] Scheme 3
[0087]
[0088] Scheme 3.Reagents and conditions:(i)LiOH,MeOH / THF,70℃;(ii)H2O2,MeCN,Trifluoroacetophenone,BuOH,buffer(K2CO3 / EDTA disodium salt=1500:1),r.t.;(iii)R7I,NaH,DMF;(iv)1)CF3COOH,0℃;2)R1OCOCl,TEA.
[0089] Scheme 4
[0090]
[0091] Scheme 4.Reagents and conditions:(i)Pd(PPh3)2Cl2,CuI,TEA,50℃;(ii)NaClO2,NaH2PO4,2-Methyl-1-butene,r.t;(iii)H2,Pt / C,CF3CH2OH,50℃;(iv)1)CF3COOH,0℃;2)R1OCOCl,TEA.
[0092] Scheme 5
[0093]
[0094] Scheme 5.Reagents and conditions: (i) (Triisopropylsilyl)acetylene, Pd(PPh3)2Cl2, CuI, TEA, 90℃; (ii) n-Bu4NF / THF, 0℃; (iii) NaClO2, NaH2PO4, 2- Methyl-1-butene,rt; (iv) LiOH, MeOH; (v) Mel, KHCO3, 0℃; (vi) 1) R6MgBr, THF / DAST, DCM, 0℃; 2) CF3COOH, DCM, 0℃; 3) R1OCOCl, TEA.
[0095] wherein said R1, R5, and R6 are as defined in claims 1-7, and R8 is selected from H, C1, C2, C3, C4, C5 straight or branched alkyl, halogen-substituted C1, C2, C3, C4, C5 straight or branched alkyl, nitro-substituted C1, C2, C3 straight or branched alkyl, (CH2)nORw1, CH2CH(CH3)CH2ORw1, (CH2)mCHCH3ORw1, CH2C(CH3)2ORw1, CH2CH(CH2CH3)ORw1, (CH2)nNRw2Rw3, CH2CH(CH3)CH2NRw2Rw3, (CH2)m CH(CH3)NRw2Rw3, CH2C(CH3)2NRw2Rw3, CH2CH(CH2CH3)NRw2Rw3, Wherein Rw1, Rw2, Rw3 are independently selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen substituted C1, C2, C3, C4 straight chain or branched alkyl; n is selected from 1, 2, 3; m is selected from 1; o is selected from 1, 2, 3, 4, 5; X is selected from CH2, NH, O; R7 is selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen substituted C1, C2, C3, C4 straight chain or branched alkyl.
[0096] The starting materials and intermediates in the above reaction are easy to obtain, and each step of the reaction can be easily synthesized according to the reported literature or by conventional methods in organic synthesis for those skilled in the art. The compound described in general formula I can exist in the form of a solvate or an unsolvate, and different solvates may be obtained by crystallization using different solvents. The pharmaceutically acceptable salts described in general formula I include salts of different acids, such as the following inorganic or organic acids: hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, trifluoroacetic acid, citric acid, maleic acid, tartaric acid, fumaric acid, citric acid, lactic acid. The pharmaceutically acceptable salts described in general formula I also include different alkali metal salts (lithium, sodium, potassium salts), alkaline earth metal salts (calcium, magnesium salts) and ammonium salts, and salts of organic bases that can provide physiologically acceptable cations, such as methylamine, dimethylamine, trimethylamine, piperidine, morpholine and tris (2-hydroxyethyl) amine salts. All of these salts within the scope of the present invention can be prepared by conventional methods.
[0097] The seventh aspect of the technical solution of the present invention is to provide a pharmaceutical composition, which comprises the compound or a pharmaceutically acceptable salt thereof as described in the first to fifth aspects of the technical solution of the present invention and a commonly used pharmaceutical carrier.
[0098] The composition comprises at least one compound of the present invention and a pharmaceutically acceptable carrier. The pharmaceutical composition is selected from tablets, capsules, pills, injections, sustained-release preparations, controlled-release preparations or various microparticle delivery systems. The pharmaceutical composition can be prepared according to methods well known in the art. Any dosage form suitable for human or animal use can be prepared by combining the compound of the present invention with one or more pharmaceutically acceptable solid or liquid excipients and / or adjuvants. The content of the compound of the present invention in its pharmaceutical composition is usually 0.1-95% by weight. The compound of the present invention or a pharmaceutical composition containing it can be administered in a unit dose form, and the route of administration can be enteral or parenteral, such as oral, intravenous, intramuscular, subcutaneous, nasal, oral mucosa, eyes, lungs and respiratory tract, skin, vagina, rectum, etc.
[0099] The dosage form can be a liquid dosage form, a solid dosage form or a semisolid dosage form. Liquid dosage forms can be solutions (including true solutions and colloidal solutions), emulsions (including o / w types, w / o types and multiple emulsions), suspensions, injections (including water injections, powder injections and infusions), eye drops, nasal drops, lotions and liniments, etc.; solid dosage forms can be tablets (including ordinary tablets, enteric-coated tablets, lozenges, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules (including hard capsules, soft capsules, enteric-coated capsules), granules, powders, micropills, dropping pills, suppositories, films, patches, aerosols (powders), sprays, etc.; semisolid dosage forms can be ointments, gels, pastes, etc.
[0100] The compound of the present invention can be made into common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle drug delivery systems.
[0101] These preparations are prepared according to methods well known to those skilled in the art. The adjuvants used to make tablets, capsules, and coatings are conventional adjuvants, such as starch, gelatin, gum arabic, silica, polyethylene glycol, and the solvents used in liquid dosage forms are, for example, water, ethanol, propylene glycol, and vegetable oils such as corn oil, peanut oil, and olive oil. The preparations containing the compounds of the present invention may also contain other adjuvants, such as surfactants, lubricants, disintegrants, preservatives, flavoring agents, pigments, and the like.
[0102] In order to prepare the compound of the present invention into tablets, various excipients known in the art can be widely used, including diluents, binders, wetting agents, disintegrants, lubricants, and glidants. The diluent may be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the wetting agent may be water, ethanol, isopropanol, etc.; the binder may be starch slurry, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinyl pyrrolidone, polyethylene glycol, etc.; the disintegrant may be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfate, etc.; the lubricant and glidant may be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc. The tablets can be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.
[0103] In order to prepare the dosing unit into a capsule, the active ingredient compound of the present invention can be mixed with a diluent and a glidant, and the mixture can be directly placed in a hard capsule or a soft capsule. The active ingredient compound of the present invention can also be first prepared into granules or pellets with a diluent, a binder, and a disintegrant, and then placed in a hard capsule or a soft capsule. The diluents, binders, wetting agents, disintegrants, and glidants used to prepare tablets of the compound of the present invention can also be used to prepare capsules of the compound of the present invention.
[0104] To prepare the compound of the present invention into an injection, water, ethanol, isopropanol, propylene glycol or a mixture thereof can be used as a solvent and an appropriate amount of a solubilizer, cosolvent, pH adjuster, and osmotic pressure regulator commonly used in the art can be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-β-cyclodextrin, etc.; the pH adjuster can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc.; the osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. If a lyophilized powder injection is prepared, mannitol, glucose, etc. can also be added as a support agent.
[0105] Furthermore, if necessary, colorants, preservatives, perfumes, flavoring agents or other additives may be added to the pharmaceutical preparations.
[0106] In order to achieve the purpose of medication and enhance the therapeutic effect, the drug or pharmaceutical composition of the present invention can be administered by any known administration method.
[0107] The dosage of the pharmaceutical composition of the compound of the present invention can vary widely according to the nature and severity of the disease to be prevented or treated, the individual conditions of the patient or animal, the route of administration and the dosage form. Generally speaking, the suitable dosage range of the compound of the present invention is 0.1-1000 mg / Kg body weight per day, preferably 1-500 mg / Kg body weight. The above dosage can be administered in one dosage unit or divided into several dosage units, depending on the doctor's clinical experience and the dosage regimen including the use of other treatment means.
[0108] The compound or composition of the present invention can be taken alone or in combination with other therapeutic drugs or symptomatic drugs. When the compound of the present invention has a synergistic effect with other therapeutic drugs, its dosage should be adjusted according to the actual situation.
[0109] The eighth aspect of the technical solution of the present invention provides the use of the compounds and pharmaceutical salts thereof described in the first to fifth aspects of the present invention in the preparation of MAO-B and / or A inhibitors, in the preparation of drugs for preventing and / or treating diseases related to MAO-B and / or A, in the preparation of drugs for treating neuropsychiatric diseases, cardiovascular system diseases, metabolic diseases, and cancer treatment drugs, especially in the preparation of drugs related to diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease (HD), depression, anxiety, amyotrophic lateral sclerosis, mania, cancer, obesity, chronic obstructive pulmonary disease or pulmonary hypertension.
[0110] Beneficial technical effects:
[0111] The isobenzofuran-1(3H)-one compounds in this patent application are MAO-B inhibitors with a completely new structure, which have significant inhibitory activity against MAOB, and some compounds also have significant inhibitory activity against MAOA. DETAILED DESCRIPTION
[0112] The invention will be further described below with reference to the embodiments, but the scope of the invention is not limited thereto.
[0113] The structure of the compound is determined by nuclear magnetic resonance (NMR) or high resolution mass spectrometry (HRMS). NMR is measured using Varian mercury 400 or Varian mercury 500, the solvent is CDCl3, DMSO-d6, MeOH-d4, the internal standard is TMS, and the chemical shift is given in ppm. mp is the melting point given in °C, and the temperature is not corrected. Silica gel column chromatography generally uses 200-300 mesh silica gel as the carrier.
[0114] List of abbreviations:
[0115] Na2CO3: Sodium carbonate; Cs2CO3: Cesium carbonate; NaHCO3: Sodium bicarbonate; K2CO3: Potassium carbonate DMAP: 4-dimethylaminopyridine; TFA: Trifluoroacetic acid; NaCl: Sodium chloride
[0116] TEA: triethylamine; DIEA: N,N-diisopropylethylamine
[0117] DMF: N,N-dimethylformamide; THF: tetrahydrofuran; PE: petroleum ether; EA: ethyl acetate; DCM: dichloromethane; MeOH: methanol; CAN: acetonitrile
[0118] Ar: argon; min: minute; rt: room temperature; h: hour
[0119] Boc anhydride: di-tert-butyl dicarbonate; TfCl: trifluoromethanesulfonyl chloride; Ac2O: acetic anhydride; Xphos: 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl; DPPF: 1,1'-bis(diphenylphosphino)ferrocene; Cbz-Cl: benzyl chloroformate; DAST: diethylaminosulfur trifluoride; NBS: N-bromosuccinimide; EDCI: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
[0120] CDCl3: deuterated chloroform; DMSO-d6: deuterated dimethyl sulfoxide; CD3OD: deuterated methanol TLC: thin-layer chromatography
[0121] Embodiment 1:
[0122] Synthesis of tert-butyl 3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0123]
[0124] (1) Synthesis of 2,2,2-trifluoro-1-(6-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (Intermediate 1)
[0125]
[0126] 6-Hydroxy-1,2,3,4-tetrahydroisoquinoline (1.3 g, 6.13 mmol) and trifluoroacetic anhydride (1.03 mL, 7.36 mmol) were dissolved in DMF (20 mL). Under Ar protection, TEA (1.70 mL, 12.26 mmol) was added and reacted in an ice-water bath for 0.5 h. After the reaction, the reaction solution was poured into ice water, extracted with EA (20 mL × 2), the organic phases were combined, washed with saturated NaCl solution (10 mL), dried over anhydrous MgSO4 and filtered to obtain a crude product, which was purified by column chromatography (SiO2, PE / EA, EA = 6%) to obtain 1.6 g of a white solid with a yield of 84.72% and a melting point of 118-120 ° C.
[0127] 1 H NMR(500MHz, CDCl3)δ(ppm)6.99(s,1H),6.78–6.70(m,1H),6.70–6.63(m,1H) ,5.75(brs,1H),4.75–4.62(m,2H),3.89–3.76(m,2H),2.89(t,J=6.0Hz,2H).
[0128] (2) Synthesis of 2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-6-yl trifluoromethanesulfonic acid (Intermediate 2)
[0129]
[0130] The intermediate 1 (600 mg, 2.45 mmol) was dissolved in 30 mL of ultra-dry DCM, TEA (1.02 mL, 7.34 mmol) was added, and the reaction vessel was placed in an ice-water bath. Under Ar protection, TfCl (0.60 mL, 5.63 mmol) was slowly added dropwise, and the reaction was carried out in an ice-water bath for 0.5 h. After the reaction was completed, the reaction was quenched with a saturated NH4Cl solution (10 mL), extracted with DCM (20 mL×3), the organic phases were combined, washed with saturated NaCl (20 mL), dried over anhydrous MgSO4, filtered and concentrated to obtain a crude product, which was purified by column chromatography (SiO2, PE / EA, EA=7%) to obtain 998 mg of a white solid with a yield of 92.67% and a melting point of 77-79°C.
[0131] 1H NMR(500MHz, CDCl3)δ(ppm)7.24–7.21(m,1H),7.18–7.15(m,1H),7.13–7.11(m,1H),4.82(s ,1.4H),4.77(s,0.6H),3.92(t,J=6.5Hz,0.6H),3.88(t,J=6.0Hz,1.4H),3.06–2.97(m,2H).
[0132] (3) Synthesis of 2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-6-carbaldehyde (Intermediate 3)
[0133]
[0134] Intermediate 2 (500 mg, 1.33 mmol) was placed in a sealed tube, and Pd(OAc)2 (15 mg, 0.066 mmol), DPPF (58 mg, 0.106 mmol), N-formyl saccharin (419 mg, 1.99 mmol) were added, and then 10 mL of ultra-dry ACN and Na2CO3 (210 mg, 1.99 mmol) were added. Under Ar protection, triethylsilane (0.32 mL, 1.99 mmol) was quickly added, and the screw cap was tightened. The reaction was heated at 80°C for 24 h. After the reaction was completed, the reaction solution was cooled to room temperature, diluted with EA (15 mL), filtered with diatomaceous earth, and the filtrate was washed with saturated NaCl (10 mL). After drying and filtration over anhydrous MgSO4, the crude product was obtained, which was purified by column chromatography (SiO2, PE / EA, EA=8%) to obtain 313 mg of a white solid with a yield of 90.01% and a melting point of 75-77°C.
[0135] 1 H NMR (500MHz, CDCl3) δ (ppm) 10.00 (s, 0.3H), 9.99 (s, 0.7H), 7.76 (d, J = 7.5Hz, 1H), 7.21 (s, 0.3H), 7.70 (s, 0.7H), 7.34 (d, J = 8.0Hz, 0.7H), 7.31 (d, J = 8.0Hz, 0.3H), 4.88 (s, 1.4H), 4.83 (s, 0.6H), 3.94 (t, J = 6.0Hz, 0.6H), 3.90 (t, J = 5.5Hz, 1.4H), 3.07–3.03 (m, 2H).
[0136] (4) Synthesis of 7-bromo-2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-6-carbaldehyde (Intermediate 4)
[0137]
[0138] Intermediate 3 (600 mg × 2, 1.26 mmol) was placed in a sealed tube, and Pd(OAc)2 (53 mg × 2, 0.233 mmol), NBS (498 mg × 2, 2.80 mmol) were added, and then ultra-dry DCE 9 mL × 2 was added, and 2-amino-5-chlorotrifluorotoluene (66 μL × 2, 0.466 mmol) was added with a pipette, and trifluoroacetic acid 1.5 mL × 2 was added. Ar was filled, the screw cap was tightened, and the reaction was heated at 60°C for 12 h. After the reaction was completed, it was cooled to room temperature, quenched with saturated NaCl (20 mL), extracted with DCM (30 mL), and the organic layer was washed with saturated NaCl (20 mL), dried and filtered with anhydrous MgSO4 to obtain a crude product, which was purified by column chromatography (SiO2, PE / EA, EA = 6%) to obtain 1.204 g of yellow crystals in total, with a yield of 76.78%.
[0139] 1 H NMR (500MHz, CDCl3) δ (ppm) 10.32 (s, 1H), 7.79 (s, 0.3H), 7.77 (s, 0.7H), 7.51 (s, 0.7H), 7.49 (s, 0.3H) ), 4.87 (s, 1.4H), 4.82 (s, 0.6H), 3.95 (t, J = 6.0Hz, 0.6H), 3.91 (t, J = 6.0Hz, 1.4H), 3.00–2.92 (m, 2H).
[0140] (5) Synthesis of tert-butyl 7-bromo-6-formyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 5)
[0141]
[0142] Dissolve intermediate 4 (3 g, 8.93 mmol) in methanol (60 mL), add saturated aqueous solution (60 mL) of K2CO3 (3.7 g, 26.78 mmol), protect with Ar, stir for 2 h in ice-water bath, then add Boc anhydride (4.86 g, 22.28 mmol). React for 2 h in ice-water bath, and the reaction is complete. Dilute with DCM (40 mL × 2), wash with saturated NaCl (60 mL), dry and filter with anhydrous MgSO4, concentrate to obtain crude product, column chromatography (SiO2, PE / EA, EA = 8%), obtain 2.04 g of white solid, yield 67.3%.
[0143] 1H NMR (500MHz, CDCl3) δ (ppm) 10.30 (s, 1H), 7.71 (s, 1H), 7.41 (s, 1H), 4.61 (s, 2H), 3.66 (t, J = 6.0Hz, 2H), 2.84 (t, J = 5.8Hz, 2H), 1.49 (s, 9H).
[0144] (6) Synthesis of tert-butyl 7-bromo-6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 6)
[0145]
[0146] Intermediate 5 (802 mg, 2.36 mmol) was dissolved in anhydrous MeOH (35 mL), and NaBH4 (133.7 mg, 3.54 mmol) was added. The mixture was stirred for 10 min in an ice-water bath, and the reaction was completed. Water (20 mL) was added to quench the mixture, and EA (15 mL×2) was used for extraction. The organic phases were combined, washed with saturated NaCl solution (20 mL), dried over anhydrous MgSO4, filtered, and concentrated to obtain a crude product. Column chromatography (SiO2, PE / DCM / EA, EA=12%) gave 554 mg of a white solid with a yield of 68.67% and a melting point of 105-107°C.
[0147] 1 H NMR (500MHz, CDCl3) δ (ppm) 7.41 (s, 1H), 7.31 (s, 1H), 4.48–4.46 (m, 4H), 3.53 (t, J = 6.0Hz, 2H), 2.74 (t, J = 6.0Hz, 2H), 1.42 (s, 9H).
[0148] (7) Synthesis of tert-butyl 3-carbonyl-1,5,7,8-tetrahydrofurano[3,4-g]isoquinoline-6(3H)-carboxylate (Example 1)
[0149]
[0150] Intermediate 6 (500 mg×6, 1.46 mmol), Pd(OAc)2 (16.4 mg×6, 0.07 mmol), Xanth-Phos (85 mg×6, 0.145 mmol), DMAP (355 mg×6, 2.92 mmol), Co2(CO)8 (120 mg×6, 0.365 mmol) were added to a microwave-sealed tube, and 8 mL of anhydrous toluene was added. The mixture was heated to 90°C in a microwave oven for 30 min. After the reaction was completed, the mixture was filtered through diatomaceous earth and concentrated to obtain a crude product. The crude product was subjected to column chromatography (SiO2, DCM / EA, EA=8-9%) to obtain 2.13 g of a white solid with a yield of 83.9% and a melting point of 115-118°C.
[0151] 1 H NMR(400MHz,DMSO-d6)δ(ppm)7.66(s,1H),7.42(s,1H),5.31(s,2H),4.56(s,2H),3. 51(t,J=6.0Hz,2H),2.88(t,J=6.0Hz,2H),1.38(s,9H); HR-MS(ESI):m / z,calcd.For C 12 H 12 O4N[(M-C4H9)+H] + 234.0761,Found:234.0775.
[0152] Embodiment 2:
[0153] Synthesis of 3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylic acid cyclopropyl methylene ester
[0154]
[0155] (1) Synthesis of 5,6,7,8-tetrahydrofuran[3,4-g]isoquinoline-3(1H)-trifluoroacetate (Intermediate 7)
[0156]
[0157] Example 1 (1.43 g, 4.94 mmol) was dissolved in anhydrous DCM (30 mL), trifluoroacetic acid (7.56 mL, 98.85 mmol) was added, and the mixture was stirred for 2 h in an ice-water bath. After the reaction was completed, a large amount of anhydrous ether (20 mL) was added, and a white solid precipitated. The filter cake was filtered and washed with anhydrous ether to obtain 600 mg of a white solid with a yield of 65.03% and a melting point of 115-117°C.
[0158] 1 H NMR(400MHz,DMSO-d6)δ(ppm)9.14(s,1H),7.80(s,1H),7.54(s,1H),5.40(s,2H),4. 38(s,2H),3.43(t,J=6.4Hz,2H),3.14(t,J=6.0Hz,2H); HR-MS(ESI):m / z,calcd.For C 11 H 12 O2N[M+H] + 190.0863,Found:190.0868.
[0159] (2) Synthesis of cyclopropylmethyl chloroformate (intermediate 8)
[0160]
[0161] Under Ar protection, cyclopropylmethanol (500 mg, 6.93 mmol) and DIEA (1.61 mL, 9.22 mmol) were placed in a dry 25 mL two-necked round-bottom flask, 10 mL of DCM was added, and then triphosgene (685 mg, 2.31 mmol) was dissolved in 10 mL of DCM and added dropwise to the reaction flask. The mixture was reacted in an ice-water bath for 0.5 h, then warmed to room temperature, stirred for 4 h, and used directly in the next step.
[0162] (3) Synthesis of 3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylic acid cyclopropylmethylene ester (Example 2)
[0163]
[0164] The intermediate 7 (100 mg, 0.528 mmol) was dissolved in ultra-dry DCM (5.0 mL), TEA (220 μL, 1.59 mmol) was added, and the reaction bottle was placed in an ice-water bath. Under Ar protection, the above-prepared cyclopropyl methyl chloroformate (6.0 mL, 1.06 mmol) was added. After reacting for about 10 min, saturated NH4Cl (10 mL) was added to quench the reaction, and DCM (20 mL) was used for extraction, and the mixture was washed with saturated NaCl (10 mL). The mixture was dried and filtered over anhydrous MgSO4 and concentrated to obtain a crude product. Column chromatography (SiO2, DCM / EA, EA=9%) was performed to obtain 71 mg of a crude product, which was washed with anhydrous ether to obtain 44 mg of a white solid with a yield of 46.76%. The melting point was 115-117°C.
[0165] 1 H NMR(400MHz,CD3OD)δ(ppm)7.76(s,1H),7.49(s,1H),5.37(s,2H),4.69(s,2H),3.91(s,2H), 3.64(s,2H),2.99(s,2H),1.13(s,1H),0.53(s,2H),0.29(s,2H); HR-MS(ESI):m / z,calcd.For C 16 H 18 O4N[M+H] + 288.1230,Found:288.1224.
[0166] Embodiment 3:
[0167] Synthesis of N-(tert-butyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxamide
[0168]
[0169] Intermediate 7 (115 mg, 0.607 mmol) was dissolved in anhydrous DCM (7 mL), and DIEA (105 μL, 0.607 mmol) was added to completely dissolve it. Ar protection, tert-butyl isocyanate (138 μL, 1.22 mmol) was added under ice-water bath, and then the temperature was raised to room temperature for reaction for 3.5 h. After the reaction was completed, water was added to quench, the reaction solution was extracted with DCM (15 mL), the organic phase was washed with saturated NaCl (10 mL) solution, dried, filtered and concentrated with anhydrous MgSO4, column chromatography (SiO2, DCM / 10% MeOH, 10% MeOH = 4%), concentrated, washed with anhydrous ether, and a white solid of 102 mg was obtained, with a yield of 66.93%, and a melting point of 165-167 ° C.
[0170] 1 H NMR(400MHz,DMSO-d6)δ(ppm)7.63(s,1H),7.46(s,1H),5.82(s,1H),5.36(s ,2H),4.57(s,2H),3.54(t,J=6.0Hz,2H),2.92(t,J=6.0Hz,2H),1.27(s,9H); 13 C NMR (150MHz, CDCl3) δ (ppm) 170.81, 156.50, 144.97, 142.69, 135.45, 124.13, 123. 49,121.93,69.52,51.10,45.55,40.82,30.05,29.50; HR-MS(ESI):m / z,calcd.For C 16 H 21 O3N2[M+H] + 289.1547,Found:289.1547.
[0171] Embodiment 4:
[0172] Synthesis of tert-butyl ester of 1-(2-aminoethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylic acid
[0173]
[0174] (1) Synthesis of tert-butyl 6-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 9)
[0175]
[0176] 1,2,3,4-Tetrahydroisoquinolin-6-ol (298 mg, 2 mmol) and Boc anhydride (436 mg, 2 mmol) were dissolved in anhydrous MeOH (3 mL). TEA (0.56 mL, 4 mmol) was added under Ar protection and reacted at room temperature for 1 h. After the reaction, the solvent was dried and EA (20 mL) was added. The organic phase was washed with water (10 mL), 1N HCl (10 mL) and saturated NaHCO3 solution (10 mL), dried over anhydrous MgSO4, filtered, and concentrated to obtain a crude product, which was purified by column chromatography (SiO2, PE / EA, EA = 15%) to obtain 332 mg of a white solid with a yield of 66.5% and a melting point of 115-117°C.
[0177] 1 H NMR (500MHz, CDCl3) δ (ppm) 6.96 (d, J = 8.5 Hz, 1H), 6.67 ( d, J = 8.5 Hz, 1H), 6.62 ( s,1H),4.49(s,2H),3.61(t,J=6.0Hz,2H),2.77(t,J=6.0Hz,2H),1.49(s,9H).
[0178] (2) Synthesis of tert-butyl 7-formyl-6-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate and tert-butyl 5-formyl-6-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 10)
[0179]
[0180] Intermediate 9 (290 mg, 1.16 mmol) was dissolved in 10 mL of ultra-dry ACN and (CH2O) was added. n (209 mg, 6.98 mmol), MgCl2 (166 mg, 1.74 mmol), and then TEA (0.6 mL, 4.3 mmol) was added dropwise. The reaction was heated under reflux for 3 h. The reaction solution changed from white turbidity to light yellow turbidity. After the reaction was completed, diatomaceous earth was filtered, the filtrate was concentrated, EA (20 mL) was added, the organic phase was washed with water (10 mL), saturated NH4Cl solution (10 mL), saturated NaHCO3 (10 mL) and saturated NaCl (10 mL), dried and filtered over anhydrous MgSO4, and concentrated to obtain a crude product, which was purified by column chromatography (SiO2, PE / EA, EA=6%) to obtain 238 mg of a light yellow solid with a yield of 73.78%.
[0181] Minor product: 1H NMR (400MHz, CDCl3) δ (ppm) 11.96 (s, 1H), 10.31 (s, 1H), 7.24 (d, J = 8.6Hz, 1H), 6.85 (d ,J=8.6Hz,1H),4.50(s,2H),3.70(t,J=6.0Hz,2H),3.15(t,J=6.0Hz,2H),1.50(s,9H);
[0182] Major products: 1 H NMR (400MHz, CDCl3) δ (ppm) 10.84 (s, 1H), 9.83 (s, 1H), 7.30 (s, 1H), 6.78 (s, 1H), 4.55 (s, 2H), 3.63 (t, J = 6.0Hz, 2H), 2.86 (t, J = 6.0Hz, 2H), 1.50 (s, 9H).
[0183] (3) Synthesis of tert-butyl 7-formyl-6-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate and tert-butyl 5-formyl-6-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 11)
[0184]
[0185] After the intermediate 10 (1 g, 3.61 mmol) and TEA (1.0 mL, 7.21 mmol) were dissolved in anhydrous DCM (18 mL), the reaction vessel was placed in an ice-water bath. TfCl (0.6 mL, 5.41 mmol) was slowly added under Ar protection, and the reaction was carried out in an ice-water bath for 1 h. After the reaction was completed, the reaction was quenched with a saturated NaHCO3 solution (10 mL), and the reaction solution was extracted with DCM (10 mL×3) three times. The organic phases were combined, washed with saturated NaCl (30 mL), dried and filtered over anhydrous MgSO4, and the filtrate was concentrated to obtain a crude product, which was purified by column chromatography (SiO2, PE / DCM / EA, PE=80%) to obtain 947 mg of the product as a yellow oil with a yield of 64.15%.
[0186] Minor product: 1 H NMR (400MHz, CDCl3) δ (ppm) 10.48 (s, 1H), 7.42 (d, J = 8.4Hz, 1H), 7.24 (d, J = 8.4 Hz,1H),4.63(s,2H),3.64(t,J=6.0Hz,2H),3.25(t,J=6.0Hz,2H),1.49(s,9H).
[0187] Major products: 1 H NMR (400MHz, CDCl3) δ (ppm) 10.21 (s, 1H), 7.73 (s, 1H), 7.18 (s, 1H), 4.65 (s, 2H), 3.69 (t, J = 6.0Hz, 2H), 2.94 (t, J = 6.0Hz, 2H), 1.49 (s, 9H).
[0188] (4) Synthesis of Benzyl Propyl-2-ynyl-1-carbamate (Intermediate 12)
[0189]
[0190] Propargylamine (100 mg, 1.82 mmol) and NaHCO3 (305 mg, 3.63 mmol) were dissolved in a mixture of ethanol / water (2 mL / 2 mL), and Cbz-Cl (286.68 μL, 2.03 mmol) was added dropwise under Ar protection and ice-water bath, and stirred for 0.5 h under ice-water bath. After the reaction was completed, water was added to quench, DCM (10 mL) was extracted, the organic layer was washed with water, saturated NaCl (5 mL), dried over anhydrous MgSO4, filtered and concentrated. Purified by column chromatography (SiO2, P / E, E=20%), 266 mg of white crystals were obtained, with a yield of 77.43%, and a melting point of 45-47°C. 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.71 (t, J = 6.0Hz, 1H), 7.43–7.24 (m, 5H), 5.04 (s, 2H), 3.80 (d, J = 2.4Hz, 1H), 3.78 (d, J = 2.8Hz, 1H), 3.10 (t, J = 2.4Hz, 1H).
[0191] (5) Synthesis of tert-butyl 6-(3-(((benzyloxy)carbonyl)amino)propyn-1-yl)-7-formyl-3,4-dihydroisoquinoline-2(1H)-carboxylate and tert-butyl 6-(3-(((benzyloxy)carbonyl)amino)propyl-1-yn-1-yl)-5-formyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 13)
[0192]
[0193] Intermediate 11 (100 mg, 244.27 μmol), Pd(PPh3)Cl2 (171 mg, 12.21 μmol) and CuI (3 mg, 24.43 μmol) were suspended in anhydrous DMF (7 mL), and TEA (68 μL, 488.55 μmol) and intermediate 12 (92 mg, 488.55 μmol) were added, and the reaction system was evacuated with a diaphragm pump. Under Ar protection, the reaction was carried out at 50 ° C for 0.5 h. After the reaction was completed, it was cooled to room temperature, diluted with EA (20 mL), and filtered with diatomaceous earth. The filtrate was washed with saturated NaHCO3 solution (15 mL), dried, filtered, and concentrated to obtain a crude product, which was purified by column chromatography (SiO2, PE / EA, EA=29%) to obtain 161 mg of a yellow oil with a yield of 92.19%. Major product: 1 H NMR(400MHz,DMSO-d6)δ(ppm)10.34(s,1H),7.89–7.85(m,1H),7.48–7.30(m,6H),5.07(s,2H),4.57( s,2H),4.14(d,J=6.0Hz,2H),3.93(s,1H),3.54(t,J=6.0Hz,2H),2.84(t,J=6.0Hz,2H),1.42(s,9H).
[0194] Minor product: 1 H NMR(400MHz,DMSO-d6)δ(ppm)10.57(s,1H),7.81–7.78(m,1H),7.48–7.30(m,6H),5.04(s,2H),4.55( s,2H),4.13(d,J=6.0Hz,2H),3.90(s,1H),3.51(t,J=5.9Hz,2H),3.08(t,J=6.0Hz,2H),1.42(s,9H).
[0195] (6) Synthesis of tert-butyl ester of (Z)-1-(2-(((benzyloxy)carbonyl)amino)ethylidene)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Intermediate 14)
[0196]
[0197] NaH2PO4 (81 mg, 668.87 μmol) was dissolved in water (3 mL), and NaClO2 (115 mg / 80%, 891.82 mmol) was added to the solution and stirred at room temperature for 10 min. Meanwhile, in another round-bottom flask, intermediate 13 (100 mg, 222.96 μmol) was dissolved in a mixed solvent of BuOH / THF (2.5 mL / 1.0 mL), and 2-methyl-2-butene (1.0 mL, 7.8 mmol) was added at room temperature, and then the aqueous phase was added dropwise to the organic phase and stirred for 1.5 h. After the reaction was completed, it was extracted with EA (10 mL×2), and the organic phases were combined and washed with saturated NaCl (10 mL), dried, filtered and concentrated with MgSO4 to obtain a crude product. Column chromatography (DCE / EA, EA=9%) gave 25 mg of a white solid with a yield of 28.97% and a melting point of 75-77°C.
[0198] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.85 (s, 1H), 7.79 (s, 1H), 7.65 (t, J = 6.4Hz, 1H), 7.37–7.33 (m, 5H), 5.85 (t ,J=6.8Hz,2H),5.05(s,2H),4.05–3.99(m,2H),3.57(t,J=5.8Hz,2H),2.95(t,J=6.0Hz,2H),1.43(s,9H)
[0199] (7) Synthesis of tert-butyl ester of 1-(2-aminoethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylic acid (Example 4)
[0200]
[0201] Intermediate 14 (150 mg, 322.92 μmol) was dissolved in trifluoroethanol (5 mL), palladium carbon (15 mg) was added, and hydrogenation was carried out at 45°C under normal pressure for 8 h, and then 20 mg of Pd / C was added, and the reaction was continued for 2 h, filtered through celite, and concentrated to obtain 80 mg of a gray solid with a yield of 74.53% and a melting point of 120-122°C.
[0202] 1H NMR (400MHz, DMSO-d6) δ (ppm) 7.68 (s, 1H), 7.46 (s, 1H), 5.68 (dd, J1 = 8.8Hz, J2 = 3.6Hz, 1H), 4.61 (s, 2H), 3.56 (t, J = 6.0Hz, 2H), 3.17 (s,2H),2.94(t,J=6.0Hz,3H),2.71(t,J=6.4Hz,2H),2.08–2.00(m,1H),1.75–1.66(m,1H),1.43(s,9H); HR-MS(ESI):m / z,calcd.For C 18 H 25 O4N2[M+H] + 333.1809,Found:333.1805.
[0203] Embodiment 5:
[0204] Synthesis of tert-butyl 1-(2-(methylamino)ethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0205]
[0206] (1) Synthesis of tert-butyl (Z)-1-(2-(((benzyloxy)carbonyl)(methyl)amino)ethylidene)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Intermediate 15)
[0207]
[0208] The intermediate 14 (188 mg, 404.72 μmol) was dissolved in DMF (10 mL), placed in an ice-water bath, Ar protected, and NaH (35 mg, 890 μmol, 60%) in DMF solution (5 mL) was added dropwise, followed by MeI (0.1 mL, 1.62 mmol) and continued to stir and react in an ice bath. After 1 h, the mixture was warmed to room temperature and continued to react for 1 h until the starting material disappeared. After the reaction was completed, water was added to quench the mixture, and the mixture was extracted with EA (30 mL). The organic phase was washed with water, saturated NaCl (20 mL), dried over anhydrous MgSO4, filtered and concentrated to obtain a crude product, which was purified by column chromatography (SiO2, P / EEA=12%) to obtain 81 mg of a white solid with a yield of 41.32% and a melting point of 76-77°C.
[0209] 1H NMR (400MHz, CDCl3) δ (ppm) 7.70–7.11 (m, 7H), 5.58–5.47 (m, 1H), 5.13 (s, 2H), 4.6 3(s,2H),4.30–4.26(m,2H),3.64(t,J=5.2Hz,2H),2.95–2.92(m,5H),1.46(s,9H).
[0210] (2) Synthesis of tert-butyl 1-(2-(methylamino)ethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Example 5)
[0211]
[0212] Intermediate 15 (81 mg, 169.26 μmol) was dissolved in trifluoroethanol (6 mL), Pd / C (20 mg) was added, and hydrogenation was carried out at 30°C in a sand bath for 5 h. The starting material disappeared, and filtered through celite to obtain 60 mg of a gray oil.
[0213] 1 H NMR (400MHz, CD3OD) δ (ppm) 7.61 (s, 1H), 7.41 (s, 1H), 5.57 (dd, J1 = 8.8Hz, J2 = 3.2Hz, 1H), 4.64 (s, 2H), 3.63 (t, J = 6.0Hz, 2H), 2.97 (t,J=6.0Hz,2H),2.87–2.70(m,2H),2.43(s,3H),2.40–2.25(m,1H),1.89–1.80(m,1H),1.47(s,9H); HR-MS(ESI):m / z,calcd.For C 19 H 27 O4N2[M+H] + 347.1965,Found:347.1972.
[0214] Embodiment 6:
[0215] Synthesis of tert-butyl 1-(2-(dimethylamino)ethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0216]
[0217] Example 4 (60 mg, 0.173 mmol) was dissolved in anhydrous DCM (6 mL), and DIEA (150 μL, 0.866 mmol) was added to completely dissolve the raw material. Ar protection was added (CH2O) n(16 mg, 0.519 mmol), stirred at room temperature for 2 h, then added NaBH(OAc)3 (147 mg, 0.693 mmol), and continued to react for 0.5 h. Add water (10 mL) to quench, extract the reaction solution with DCM (20 mL), wash with saturated NaCl (10 mL), dry with anhydrous MgSO4, filter and concentrate to obtain a crude product. Purify by column chromatography (SiO2, DCM / MeOH, MeOH=7%) to obtain 31 mg of a colorless oil, with a yield of 49.66%.
[0218] 1 H NMR (400MHz, CD3OD) δ (ppm) 7.63 (s, 1H), 7.44 (s, 1H), 5.57 (dd, J1 = 8.4Hz, J2 = 3.2Hz, 1H), 4.66 (s, 2H), 3.66 (t, J = 6.0Hz, 2H), 3.00 (t ,J=6.0Hz,2H),2.62–2.55(m,1H),2.52–2.45(m,1H),2.32–2.26(m,7H),1.89–1.80(m,1H),1.49(s,9H); HR-MS(ESI):m / z,calcd.For C 20 H 29 O4N2[M+H] + 361.2122,Found:361.2127.
[0219] Embodiment 7:
[0220] Synthesis of tert-butyl 1-fluoro-1-methyl-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0221]
[0222] (1) Synthesis of tert-butyl 7-formyl-6-((triisopropylsilyl)ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 16)
[0223]
[0224] Intermediate 11 (1.00 g, 2.44 mmol), Pd(PPh3)2Cl2 (51 mg, 0.073 mmol) and CuI (9 mg, 0.048 mmol) were suspended in anhydrous DMF (20 mL), and TEA (0.8 mL, 4.89 mmol) and triisopropylsilyl acetylene (1.1 mL, 4.89 mmol) were added to the suspension, and the reaction system was evacuated with a diaphragm pump. Under Ar protection, the reaction was carried out at 90 ° C for 2 h. After the reaction was completed, it was cooled to room temperature, diluted with EA (30 mL), and filtered with diatomaceous earth. The filtrate was washed with saturated NaHCO3 solution (20 mL), and the organic phase was dried, filtered, and concentrated to obtain a crude product, which was purified by column chromatography (SiO2, PE / EA, EA=7%) to obtain 1 g of a yellow oil with a yield of 92.68%.
[0225] Minor product: 1 H NMR (500MHz, CDCl3) δ (ppm) 10.81 (s, 1H), 7.45 (d, J = 8.0Hz, 1H), 7.24 (d, J = 8.0Hz, 1H) ,4.60(s,4H),3.59(t,J=6.0Hz,2H),3.25(t,J=6.0Hz,2H),1.49(s,9H),1.13(s,21H);
[0226] Major products: 1 H NMR (500MHz, CDCl3) δ (ppm) 10.54 (s, 1H), 7.67 (s, 1H), 7.37 (s, 1H), 4.61 (s, 2H),3.65(t,J=6.0Hz,2H),2.87(t,J=6.0Hz,2H),1.49(s,9H),1.13(s,21H).
[0227] (2) Synthesis of tert-butyl 6-ethynyl-7-formyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 17)
[0228]
[0229] Under Ar protection, 50 mL of THF was added to the intermediate 16 (2.75 g, 6.17 mmol), and the reaction bottle was placed in a -40 ° C low temperature reactor. After stirring for 20 min, tetrabutylammonium fluoride solution (8.02 mL, 8.02 mmol) was injected into the reaction bottle. After stirring for 5 min, TLC showed that the reaction was complete. The mixture was warmed to room temperature, quenched with water (30 mL), extracted with EA (30 mL × 2), washed with saturated NaCl solution (20 mL), dried over anhydrous MgSO4, and filtered to obtain a crude product. The product was purified by column chromatography (SiO2, PE / EA, EA = 9%) to obtain 1.432 g of a yellow-brown solid with a yield of 81.31%.
[0230] Minor product: 1 H NMR (500MHz, CDCl3) δ (ppm) 10.76 (s, 1H), 7.50 (d, J = 8.0Hz, 1H), 7.30 (d, J = 7.5Hz, 1H) ,4.64(s,2H),3.63(t,J=5.5Hz,2H),3.49(s,1H),3.26(d,J=6.0Hz,2H),1.52(s,9H).
[0231] Major products: 1 H NMR (500MHz, CDCl3) δ (ppm) 10.48 (s, 1H), 7.70 (s, 1H), 7.42 (s, 1H), 4.64 (s, 2H), 3.69 (t, J = 5.5Hz, 2H), 3.44 (s, 1H), 2.90 (t, J = 6.0Hz, 2H), 1.52 (s, 9H).
[0232] (3) Synthesis of tert-butyl 1-methylene-3-carbonyl-1,5,7,8-tetrahydrofuro[3,4-g]isoquinoline-6(3H)-carboxylate (Intermediate 18)
[0233]
[0234] NaH2PO4 (2.63 g, 22.93 mmol) was dissolved in water (40 mL), NaClO2 (3.31 g / 80%, 29.24 mmol) was added to the solution and stirred at room temperature for 10 min. Meanwhile, in another round-bottom flask, intermediate 17 (2.09 g, 7.31 mmol) was dissolved in a mixed solvent of BuOH / THF (30 mL / 15 mL), and 2-methyl-2-butene (25 mL, 255.87 mmol) was added at room temperature, and then the aqueous phase was added dropwise to the organic phase and stirred at room temperature for 4.5 h. Diluted with EA (30 mL×2), washed with saturated NaCl (20 mL), dried with anhydrous MgSO4 and filtered to obtain a crude product. Purified by column chromatography (PE / EA, EA=8%; DCM / EA, DCM=0%), 616 mg of a white solid was obtained, with a yield of 21%, and a melting point of 125-127°C.
[0235] 1 H NMR (500MHz, CDCl3) δ (ppm) 7.65 (s, 1H), 7.49 (s, 1H), 5.19 (d, J = 3.0Hz, 1H), 5.16 (d, J=3.0Hz,1H),4.68(s,2H),3.68(t,J=6.0Hz,2H),2.99(t,J=6.0Hz,2H)1.50(s,9H); 13 C NMR (150MHz, CDCl3) δ (ppm) 166.62, 154.64, 151.66, 142.82, 137.31, 123.51, 123.05, 120. 65,90.75,80.40,46.21(45.44),41.33(40.23),30.03,28.45; HR-MS(ESI):m / z,calcd.For C 13 H 12 O4N[(M-C4H9)+H] + 246.0761,Found:246.0759.
[0236] (4) Synthesis of 6-acetyl-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid (Intermediate 19)
[0237]
[0238] Intermediate 18 (100 mg, 331.85 μmol) was dissolved in a mixed solvent of MeOH and THF (2 mL), and an aqueous solution of LiOH (24 mg, 995 μmol) (1 mL) was added dropwise at room temperature, and the mixture was protected with Ar and reacted at 45°C for 3 h. After the reaction, the solvent was dried by spin drying, diluted with water (10 mL), extracted with ether (5 mL), and the pH value of the aqueous phase was adjusted to 3-4 with 1N HCl (10 mL). A white solid precipitated and was filtered to obtain 85 mg of a white solid with a yield of 80.2% and a melting point of 156-158°C.
[0239] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.79–7.21 (m, 2H), 4.60 (s, 1H), 4.56 (s, 1H), 3.56 (t, J = 6.0Hz, 2H), 2.95–2.82 (m, 2H), 1.43 (s, 9H).
[0240] (5) Synthesis of tert-butyl 1-fluoro-1-methyl-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Example 7)
[0241]
[0242] Intermediate 19 (60 mg, 187.88 μmol) was dissolved in DCM (6 mL), placed in an ice-water bath, and DAST (25 μL, 187.88 μmol) was added under Ar protection. After 0.5 h, the temperature was raised to room temperature. After 1 h, a large amount of raw material still remained. 1 eq DAST (25 μL, 187.88 μmol) was added. After 1 h, there was still raw material remaining. TLC showed no obvious change, and the reaction was stopped. Water (10 mL) was added to quench the reaction, and the reaction solution was extracted with EA (10 mL×2). The organic phases were combined, washed with saturated NaCl (5 mL), dried over anhydrous MgSO4, filtered and concentrated to obtain a crude product, which was purified by column chromatography (SiO2, D / E EA=4%, EA=8%) to obtain 10 mg of a white solid with a yield of 17% and a melting point of 103-105°C.
[0243] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.62 (s, 1H), 7.38 (s, 1H), 4.67 (s, 2H), 3.68 (t, J = 6.0Hz, 2H) ,2.98(t,J=6.0Hz,2H),1.97(d,J=18.0Hz,3H),1.48(s,9H); HR-MS(ESI):m / z,calcd.For C 17 H 21 O4NF[M+H] +322.1449,Found:322.1450.
[0244] Embodiment 8:
[0245] Synthesis of tert-butyl 1,1-dimethyl-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0246]
[0247] (1) Synthesis of 2-(tert-butyl)-7-methyl-6-acetyl-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate (Intermediate 20)
[0248]
[0249] Intermediate 19 (343 mg, 0.156 mmol) was dissolved in DMF (10 mL), NaHCO3 (118 mg, 1.18 mmol) was added, MeI (0.7 mL, 10.74 mmol) was added under Ar protection, and the temperature was raised to 70°C for 6 h. After the reaction was completed, part of the alkali was removed by filtration, the filtrate was diluted with EA (20 mL), the organic phase was washed with saturated NaCl (10 mL), dried, filtered and concentrated to obtain a crude product. Column chromatography (SiO2, PE / EA, EA=20%) was used for purification to obtain 343 mg of a light yellow oil with a yield of 88.09%.
[0250] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.61 (s, 1H), 7.17 (s, 1H), 4.61 (s, 2H), 3.88 (s, 3H), 3.65 (t, J = 6.0Hz, 2H), 2.88 (t, J = 6.0Hz, 2H), 2.51 (s, 3H), 1.49 (s, 9H).
[0251] (2) Synthesis of tert-butyl 1,1-dimethyl-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Example 8)
[0252]
[0253] The intermediate 20 (343 mg, 1.03 mmol) was dissolved in THF, and Ar was protected. Methylmagnesium bromide (0.72 mL, 2.16 mmol) in ether (3 M) was added dropwise to the reaction solution under ice-water bath conditions, and the reaction was continued for 0.5 h under ice-water bath conditions. The reaction was stopped, quenched with water, extracted with DCM (30 mL), and the organic layer was washed with saturated NH4Cl (20 mL), saturated NaCl (20 mL), dried over anhydrous MgSO4, filtered and concentrated to obtain a crude product, which was purified by column chromatography (SiO2, PE / EA, EA=8%) to obtain 135 mg of a white solid with a yield of 41.35% and a melting point of 103-105°C.
[0254] 1H NMR (400MHz, DMSO-d6) δ (ppm) 7.60 (s, 1H), 7.49 (s, 1H), 4.56 (s, 2H), 3.52 (t, J = 6.0H z,2H),2.88(t,J=6.0Hz,2H),1.55(s,6H),1.38(s,9H); HR-MS(ESI):m / z,calcd.For C 14 H 16 O4N[(M-C4H9)+H] + 262.1074,Found:262.1088.
[0255] Embodiment 9:
[0256] Synthesis of tert-butyl 1-(nitromethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0257]
[0258] (1) Synthesis of 2-(tert-butoxycarbonyl)-6-(((trifluoromethyl)sulfonyl)oxy)-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid (Intermediate 21)
[0259]
[0260] NaH2PO4 (1.05 g, 8.72 mmol) was dissolved in water (20 mL), NaClO2 (1.31 g / 80%, 11.63 mmol) was added to the solution, and stirred at room temperature for 10 min. Meanwhile, in another round-bottom flask, intermediate 11 (1.19 g, 2.91 mmol) was dissolved in a mixed solvent of BuOH / THF (18 mL / 4 mL), and 2-methyl-2-butene (12 mL, 101.74 mmol) was added at room temperature. The organic phase was added dropwise to the aqueous phase at room temperature and heated to 45°C and continued to stir and react for 3 h. After the reaction was completed, it was diluted with EA (40 mL), the organic phase was washed with saturated NaCl (10 mL), dried, filtered, and concentrated to obtain a crude product of white solid 1.18 g, with a yield of 95.43%. The crude product was recrystallized with EtOH at 80°C to obtain 590 mg of white solid, with a yield of 40%, and a melting point of 95-97°C.
[0261] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.84 (s, 1H), 7.30 (s, 1H), 4.54 (s, 2H), 3.52 (t, J = 5.8Hz, 2H), 2.84 (t, J = 5.9Hz, 2H), 1.38 (s, 9H).
[0262] (2) Synthesis of 2-(tert-butyl)7-methyl 6-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate (Intermediate 22)
[0263]
[0264] The intermediate 21 (200 mg, 470.71 μmol) was dissolved in DMF (7 mL), KHCO3 (57 mg, 564.21 μmol) was added, and the mixture was stirred at room temperature for 5 min under Ar protection, and then MeI (0.1 mL, 1.41 mmol) was added, and the mixture was heated at 40°C for 0.5 h. After the reaction was completed, the mixture was filtered, and the filtrate was diluted with EA (20 mL). The organic phase was washed with saturated NaCl (10 mL), dried, filtered, and concentrated to obtain a crude product. The mixture was purified by column chromatography (SiO2, PE / EA, EA=12%) to obtain 159 mg of a light yellow solid with a yield of 76.96% and a melting point of 172-174°C. 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.92 (s, 1H), 7.39 (s, 1H), 4.61 (s, 2H), 3.88 (s, 3H), 3.58 (t, J = 6.0Hz, 2H), 2.90 (t, J = 6.0Hz, 2H), 1.45 (s, 9H).
[0265] (3) Synthesis of 2-(tert-butyl)-7-methyl-6-vinyl-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate (Intermediate 23)
[0266]
[0267] The intermediate 22 (3.71 g, 11.67 mmol) was dissolved in a mixed solvent of MeOH (20 mL) and THF (10 mL), and a solution of LiOH (840 mg, 35.07 mmol) in water (10 mL) was added dropwise at room temperature, and the mixture was reacted at 70°C for 3 h under Ar protection. After the reaction, the solvent was dried, water (10 mL) was added, and the mixture was extracted with ether (10 mL×2). The pH value of the aqueous phase was adjusted to 3-4 with 2N HCl, and a white solid was precipitated. The mixture was filtered and the filter cake was washed with water to obtain 3.3 g of a white solid with a yield of 93.67% and a melting point of 145-147°C.
[0268] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.62 (s, 1H), 7.50 (s, 1H), 7.31 (dd, J1 = 17.6Hz, J2 = 11.2Hz, 1H), 5.73 (dd, J1 = 17.6Hz, J2 = 1.6Hz, 1H), 5.32 (dd, J1 = 11.2Hz, J2 = 1.2Hz, 1H), 4.53 (s, 2H), 3.82 (s, 3H), 3.56 (t, J = 5.9Hz, 2H), 2.84 (t, J = 6.0Hz, 2H), 1.43 (s, 9H).
[0269] (4) Synthesis of 2-(tert-butyl)-7-methyl-6-formyl-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate (Intermediate 24)
[0270]
[0271] NaIO4 (5.07 g, 23.50 mmol) and K2O4Os 2H2O (549 mg, 1.76 mmol) were dissolved in 40 mL of water and placed at -10°C. A solution of intermediate 23 (3.73 g, 11.75 mmol) in ACN (40 mL) was added dropwise. After the addition was completed, the temperature was gradually raised to 0°C and reacted for 40 min. The raw material basically disappeared. After the reaction was completed, diatomaceous earth was filtered, the filtrate was diluted with EA (100 mL), the organic layer was washed with saturated sodium chloride (50 mL), dried over MgSO4, filtered and concentrated. Purification by column chromatography (SiO2, PE / EA, EA=14%) gave 1.25 g of a white solid with a yield of 33.54% and a melting point of 130-132°C.
[0272] 1 H NMR (400MHz, CDCl3) δ (ppm) 10.61 (s, 1H), 7.75 (s, 1H), 7.74 (s, 1H), 4.66 (s, 2H),3.97(s,3H),3.68(t,J=6.0Hz,2H),2.93(t,J=6.0Hz,2H),1.50(s,9H).
[0273] (5) Synthesis of 2-(tert-butyloxycarbonyl)-6-(1-hydroxy-2-nitroethyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid (Intermediate 25)
[0274]
[0275] The intermediate 24 (100 mg, 313.13 μmol) was dissolved in MeOH (10 mL), and MeNO2 (50 μL, 939 μmol) was added, followed by a dropwise addition of an aqueous NaOH solution (39 mg, 939 μmol). After the addition was complete, the reaction was allowed to react at room temperature for 3 h, and the raw material disappeared. The reaction solution was added dropwise with a 1N HCl aqueous solution (5 mL) under an ice-water bath to adjust the pH value to about 3, and a white solid precipitated from the reaction solution. The filter cake was filtered and washed with water several times to obtain 84 mg of a white solid, with a yield of 73.22%, and a melting point of 185-187°C.
[0276] 1 H NMR(400MHz,DMSO-d6)δ(ppm)7.69(s,1H),7.59(s,1H),6.09–6.03(m,2H),4.81–4.78(m,1H ),4.53(s,2H),4.40–4.35(m,1H),3.57(t,J=5.8Hz,2H),2.83(t,J=6.0Hz,2H),1.42(s,9H).
[0277] (6) Synthesis of tert-butyl 1-(nitromethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Example 9)
[0278]
[0279] Intermediate 25 (1.35 g, 3.67 mmol), EDCI (768 mg, 4.03 mmol), DMAP (48 mg, 366.88 μmol) were dissolved in DMF (20 mL), stirred at room temperature for 3 h, then the reaction solution was poured into ice water, extracted with EA (20 mL×3), the organic phases were combined, washed with water (20 mL), washed with saturated NaCl (20 mL), dried over MgSO4, filtered and concentrated to obtain a crude product. Purified by column chromatography (SiO2, PE / EA, EA=11%), 988 mg of a white solid was obtained, with a yield of 76.97%, and a melting point of 205-207°C.
[0280] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.62 (s, 1H), 7.58 (s, 1H), 6.20 (dd, J1 = 7.6Hz, J2 = 2.4Hz, 1H), 5.46 (dd, J1 = 14.8Hz, J2 = 4.8Hz, 1H), 5.0 For C 13 H 13 O6N2[(M-C4H9)+H] + 293.0768,Found:293.0765.
[0281] Embodiment 10:
[0282] Synthesis of tert-butyl 1-(aminomethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0283]
[0284] Example 9 (588 mg, 1.69 mmol) was dissolved in trifluoroethanol (22 mL), Pd / C (118 mg) was added, and the reaction was carried out under normal pressure at 65°C in a sand bath for 16 h. The raw material disappeared. The filtrate was filtered through diatomaceous earth and concentrated to obtain a crude product. The crude product was purified by column chromatography (SiO2, DCM / MeOH, MeOH=7%) to obtain 200 mg of a white solid with a yield of 37.22% and a melting point of 135-137°C.
[0285] 1H NMR (400MHz, DMSO-d6) δ (ppm) 7.68 (s, 1H), 7.50 (s, 1H), 5.47 (t, J = 5.2Hz, 1H), 4.61 (s, 2H), 3.56 (t, J = 6.0 Hz, 3H), 3.07 (dd, J1=13.6Hz, J2=4.4Hz, 1H), 3.00–2.84 (m, 3H), 1.46 (s, 9H); HR-MS (ESI): m / z, calcd.For C 17 H 23 O4N2[M+H] + 319.1652,Found:319.1647.
[0286] Embodiment 11:
[0287] Synthesis of tert-butyl 1-((dimethylamino)methyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0288]
[0289] Example 10 (50 mg, 0.155 mmol) was dissolved in anhydrous DCM (5 mL), and DIEA (137 μL, 0.785 mmol) was added to completely dissolve the raw material. Ar protection, (CH2O) was added n (18 mg, 0.627 mmol), stirred for 3 h in an ice-water bath, then added NaBH(OAc)3 (137 mg, 0.785 mmol), and continued to react for 2 h in an ice-water bath. Water (20 mL) was added to the reaction solution to quench, extracted with DCM (10 mL×2), the organic phases were combined, washed with saturated NaCl (10 mL), dried over anhydrous MgSO4, filtered, and concentrated to obtain a crude product. Column chromatography purification (SiO2, DCM / MeOH, MeOH=6%) gave 15 mg of a white solid, with a yield of 71%, and a melting point of 138-140°C.
[0290] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.65 (s, 1H), 7.46 (s, 1H), 5.63 (dd, J1 = 7.6Hz, J2 = 4.0Hz, 1H), 4.57 (s, 2H), 3.52 (t, J = 6.0Hz, 2H), 2.89 (t, J = 6 .0Hz,2H),2.81(dd,J1=13.2Hz,J2=3.6Hz,1H),2.53(dd,J1=13.6Hz,J2=7.6Hz,1H),2.23(s,6H),1.39(s,9H); HR-MS(ESI):m / z,calcd.For C19 H 27 O4N2[M+H] + 347.1965,Found:347.1966.
[0291] Embodiment 12:
[0292] Synthesis of tert-butyl 1-((methylamino)methyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0293]
[0294] (1) Synthesis of tert-butyl ((((benzyloxy)carbonyl)amino)methyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Intermediate 26)
[0295]
[0296] Example 10 (200 mg, 628.19 μmol) was dissolved in DCM (18 mL), Ar protected, DIEA (219 μL, 1.26 mmol) was added, and a solution of benzyl chloroformate (132 μL, 942.29 μmol) in DCM (5 mL) was added at 0°C, and the reaction was allowed to proceed for 10 min. TLC showed that the starting material disappeared, the reaction was stopped, and water (20 mL) was added to quench the reaction. The reaction solution was extracted with DCM (10 mL×2), the organic layers were combined, washed with saturated NH4Cl (10 mL), washed with saturated NaCl (10 mL), dried over anhydrous MgSO4, filtered, and concentrated. Purified by column chromatography (SiO2, DCM / MeOH, MeOH=5%), 286 mg of a white solid was obtained, with a yield of 99.9%, and a melting point of 80-82°C.
[0297] 1 H NMR(400MHz, CDCl3)δ(ppm)7.64(s,1H),7.37–7.27(m,6H),5.53–5.51(m,1H),5.12–5.02(m,3H),4.67( s,2H),3.98–3.91(m,1H),3.65(t,J=6.0Hz,2H),3.49–3.34(m,1H),2.94(t,J=6.0Hz,2H),1.50(s,9H).
[0298] (2) Synthesis of tert-butyl 1-((((benzyloxy)carbonyl)(methyl)amino)methyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Intermediate 27)
[0299]
[0300] Intermediate 26 (140 mg, 309.6 μmol) was dissolved in DMF (10 mL), and Ar was protected. A solution of NaH (14 mg, 402.22 μmol) in DMF (5 mL) was added under ice-water bath, and then MeI (75 μL, 1.24 mmol) was added to react for 0.5 h. TLC showed that the starting material disappeared, and the reaction was stopped. The reaction solution was poured into ice water, extracted with EA (10 mL×4), and the organic layers were combined, washed with saturated NH4Cl (10 mL), washed with saturated NaCl (10 mL), dried over anhydrous MgSO4, filtered and concentrated. Purification by column chromatography (SiO2, DCM / MeOH, MeOH=5%) gave 126 mg of a white solid, with a yield of 86.6%, and a melting point of 90-92°C.
[0301] 1 H NMR(400MHz,DMSO-d6)δ(ppm)7.67(s,1H),7.49–7.19(m,6H),5.74–5.70(m,1H),5.11–4.80(m,2H), 4.56(s,2H),3.85(d,J=14.4Hz,1H),3.67–3.57(m,1H),3.48(s,2H),2.90–2.85(m,5H),1.38(s,9H).
[0302] (3) Synthesis of tert-butyl 1-((methylamino)methyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Example 12)
[0303]
[0304] Intermediate 27 (125 mg, 267.93 μmol) was dissolved in trifluoroethanol (6 mL), Pd / C (25 mg) was added, and the reaction was hydrogenated at room temperature and pressure for 3 h. TLC showed that the starting material disappeared. The filtrate was filtered through diatomaceous earth and concentrated to obtain a colorless oil, which was then purified by column chromatography (SiO2, DCM / MeOH, MeOH=4-6%) to obtain 45 mg of a gray solid with a yield of 42.5% and a melting point of 95-97°C.
[0305] 1H NMR (400MHz, DMSO-d6) δ (ppm) 7.68 (s, 1H), 7.50 (s, 1H), 5.61 (t, J = 5.2Hz, 1H), 4.61 (s, 2H), 3.56 (t, J = 6.0Hz, 2H), 3.05 (dd, J1 = 13.2 Hz, J2=4.0Hz, 1H), 2.93 (t, J=6.0Hz, 2H), 2.82 (dd, J1=13.2Hz, J2=6.4Hz, 1H), 2.30 (s, 3H), 1.43 (s, 9H); HR-MS (ESI): m / z, calcd.For C 18 H 25 O4N2[M+H] + 333.1809,Found:333.1817.
[0306] Embodiment 13:
[0307] Synthesis of tert-butyl 1-(hydroxymethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0308]
[0309] (1) Synthesis of 2-(tert-butyloxycarbonyl)-6-vinyl-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid (Intermediate 28)
[0310]
[0311] The intermediate 23 (3.71 g, 11.67 mmol) was dissolved in a mixed solvent of MeOH (20 mL) and THF (10 mL), and a solution of LiOH (840 mg, 35.07 mmol) in water (10 mL) was added dropwise at room temperature, and the mixture was reacted at 70°C for 3 h under Ar protection. After the reaction, the solvent was dried, water (10 mL) was added, and the mixture was extracted with ether (10 mL×2). The pH value of the aqueous phase was adjusted to 3-4 with 2N HCl, and a white solid was precipitated. The mixture was filtered and the filter cake was washed with water to obtain 3.3 g of a white solid with a yield of 93.67% and a melting point of 145-147°C.
[0312] 1H NMR (400MHz, DMSO-d6) δ (ppm) 12.88 (s, 1H), 7.62 (s, 1H), 7.47 (s, 1H), 7.41 (dd, J1 = 17.6Hz, J2 = 11.2Hz, 1H), 5.71 (dd, J1 = 17.6 Hz,J2=1.6Hz,1H),5.29(dd,J1=11.2Hz,J2=1.6Hz,1H),4.52(s,2H),3.56(t,J=6.0Hz,2H),2.83(t,J=6.0Hz,2H),1.43(s,9H).
[0313] (2) Synthesis of tert-butyl 1-(hydroxymethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Example 13)
[0314]
[0315] The intermediate 28 (3.32 g, 10.94 mmol) was dissolved in BuOH (30 mL), 2,2,2-trifluoroacetophenone (762 mg, 4.38 mmol) was added, followed by 20 mL of buffer (K2CO3 / EDTA disodium salt = 1500:1) solution and ACN (7.2 mL, 175.11 mmol), and finally 30% H2O2 (17.89 mL, 175.11 mmol) was added and stirred at room temperature for 6 h. After the reaction was completed, 2N HCl (30 mL) solution was added to quench the reaction, the reaction solution was extracted with EA (50 mL), the organic phase was washed with saturated NaCl (40 mL), dried over anhydrous MgSO4, filtered and concentrated. Purification by column chromatography (SiO2, DCM / MeOH, MeOH = 3-4%) gave 2.5 g of a white solid with a yield of 71.66% and a melting point of 154-155°C.
[0316] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.68 (s, 1H), 7.48 (s, 1H), 5.55 (t, J = 4.4Hz, 1H), 4.61 (s, 2H), 3.90 (dd, J1 = 12.4Hz, J2 = 4.0Hz, 1H ), 3.73 (dd, J1 = 12.4Hz, J2 = 4.8Hz, 1H), 3.56 (t, J = 6.0Hz, 2H), 2.93 (t, J = 6.0Hz, 2H), 1.43 (s, 9H); HR-MS (ESI): m / z, calcd.ForC 13 H 14 O5N[(M-C4H9)+H] +264.0866,Found:264.0879.
[0317] Embodiment 14:
[0318] Synthesis of tert-butyl 1-(methoxymethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0319]
[0320] Example 13 (2.5 g, 7.83 mmol) was dissolved in DMF (20 mL), the reaction flask was placed in an ice-water bath, Ar protected, NaH (469.65 mg, 11.74 mmol) in DMF solution (15 mL) was added dropwise, followed by MeI (2.2 g, 15.66 mmol), and the mixture was heated to room temperature for 1 h to react. After the reaction was completed, water (20 mL) was added to quench, the reaction solution was extracted with EA (10 mL×3), the organic phases were combined, washed with water (20 mL), washed with saturated NaCl (20 mL), dried over anhydrous MgSO4, and purified by column chromatography (SiO2, P / E EA=9%) to obtain 1.68 g of a white solid with a yield of 64.3% and a melting point of 100-102°C.
[0321] 1 H NMR (400MHz, MD3OD) δ (ppm) 7.62 (s, 1H), 7.42 (s, 1H), 5.59 (t, J = 4.8Hz, 1H), 4.64 (s, 2H), 3.85 (dd, J1 = 10.8Hz, J2 = 3.2Hz, 1H), 3.70 (dd, J1=11.2Hz, J2=5.2Hz, 1H), 3.63 (t, J=6.0Hz, 2H), 3.33 (s, 3H), 2.97 (t, J=6.0Hz, 2H), 1.47 (s, 9H); HR-MS (ESI): m / z, calcd.For C 14 H 16 O5N[(M-C4H9)+H] + 278.1023,Found:278.1041.
[0322] Embodiment 15:
[0323] Synthesis of 1-(Methoxymethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylic acid cyclohexyl ester
[0324]
[0325] (1) Synthesis of 1-(methoxymethyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one (Intermediate 29)
[0326]
[0327] Example 14 (160 mg, 0.479 mmol) was dissolved in anhydrous DCM (8 mL), trifluoroacetic acid (0.74 mL, 9.60 mmol) was added in an ice-water bath, and stirred in an ice-water bath for 1 h. The mixture was concentrated, and the excess trifluoroacetic acid was removed by spin drying with a small amount of DCM several times. A large amount of ammonia water was then added to separate the residues. No solid was precipitated, and the residue was extracted with DCM (20 mL), dried and concentrated with MgSO4 to obtain 76 mg of a colorless oil, 67.89%.
[0328] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.48 (s, 1H), 7.18 (s, 1H), 5.44 (t, J = 5.2Hz, 1H), 4.05 (s ,2H),3.75–3.59(m,2H),3.37(s,3H),3.11(t,J=6.0Hz,2H),2.89(t,J=6.0Hz,2H).
[0329] (2) Synthesis of cyclohexyl chloroformate (intermediate 30)
[0330]
[0331] Under Ar protection, cyclohexanol (500 mg, 4.99 mmol) and DIEA (1.61 mL, 6.64 mmol) were placed in a dry 25 mL two-necked round-bottom flask, 5 mL of DCM was added, and then triphosgene (489 mg, 1.65 mmol) was dissolved in 5 mL of DCM and added dropwise to the reaction flask. The mixture was reacted in an ice-water bath for 0.5 h, then warmed to room temperature, stirred for 4 h, and used directly in the next step.
[0332] (3) Synthesis of 1-(methoxymethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylic acid cyclohexyl ester (Example 15)
[0333]
[0334] The intermediate 29 (100 mg, 0.428 mmol) was dissolved in ultra-dry DCM (5.0 mL), TEA (178 μL, 1.29 mmol) was added, and the reaction bottle was placed in an ice-water bath. Under Ar protection, the intermediate 30 (0.856 mmol, 1.3 mL) was added. After reacting for about 10 min, water (10 mL) was added to quench the reaction, and DCM (10 mL) was extracted. The organic phase was washed with saturated NaCl (10 mL), dried over anhydrous MgSO4, and filtered. Column chromatography (SiO2, DCM / EA, EA=6-22%) was performed to obtain 80 mg of a white solid, which was washed with anhydrous ether to obtain 44 mg of a white solid. The yield was 51.92%, and the melting point was 103-105°C.
[0335] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.65 (s, 1H), 7.28 (s, 1H), 5.49 (t, J = 5.2Hz, 1H), 4.76–4.71 (m, 1H), 4.69 (s, 2H), 3.79–3.67 (m, 4H) ),3.41(s,3H),2.97(t,J=6.0Hz,2H),1.87–1.84(m,2H),1.79–1.65(m,2H),1.56–1.31(m,6H); HR-MS(ESI):m / z,calcd.ForC 20 H 26 O5N[M+H] + 360.1805,Found:360.1800.
[0336] Embodiment 16:
[0337] Synthesis of Cyclopentyl Methyl 1-(Methoxymethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0338]
[0339] (1) Synthesis of cyclopentylmethyl chloroformate (Intermediate 31)
[0340]
[0341] Under Ar protection, cyclopentanemethanol (500 mg, 4.99 mmol) and DIEA (1.61 mL, 6.64 mmol) were placed in a dry 25 mL two-necked round-bottom flask, 5 mL of DCM was added, and triphosgene (489 mg, 1.65 mmol) was dissolved in 5 mL of DCM and added dropwise to the reaction flask. The mixture was reacted in an ice-water bath for 0.5 h, then warmed to room temperature, stirred for 4 h, and used directly in the next step.
[0342] (2) Synthesis of cyclopentylmethyl 1-(methoxymethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Example 16)
[0343]
[0344] The intermediate 29 (70 mg, 0.343 mmol) was dissolved in ultra-dry DCM (5.0 mL), and TEA (143 μL, 1.03 mmol) was added. The reaction bottle was placed in an ice-water bath. Under Ar protection, the intermediate 31 (1.0 mL, 0.686 mmol) was added and reacted for about 10 min. Saturated NH4Cl (10 mL) was added to quench the reaction, and it was extracted with DCM (10 mL×2). The organic phases were combined, washed with saturated NaCl (10 mL), dried over anhydrous MgSO4, filtered and concentrated, and column chromatography (SiO2, DCM / EA, EA=6-22%) was performed to obtain 39 mg of a white solid with a yield of 31.64% and a melting point of 90-92°C.
[0345] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.65 (s, 1H), 7.28 (s, 1H), 5.49 (t, J = 4.4Hz, 1H), 4.70 (s, 2H), 4.01 (d, J = 6.8Hz, 2H), 3.78 –3.69(m,4H),3.41(s,3H),2.97(t,J=6.0Hz,2H),2.28–2.17(m,1H),1.81–1.54(m,8H); HR-MS(ESI):m / z,calcd.For C 20 H 26 O5N[M+H] + 360.1806,Found:360.1805.
[0346] Embodiment 17:
[0347] Synthesis of Cyclobutyl Methyl 1-(Methoxymethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0348]
[0349] (1) Synthesis of cyclobutylmethyl chloroformate (Intermediate 32)
[0350]
[0351] Under Ar protection, cyclobutane methanol (400 mg, 4.64 mmol) and DIEA (1.08 mL, 6.18 mmol) were placed in a dry 25 mL two-necked round-bottom flask, 5 mL of DCM was added, and then triphosgene (455 mg, 1.53 mmol) was dissolved in 5 mL of DCM and added dropwise to the reaction flask. After reacting in an ice-water bath for 0.5 h, the mixture was warmed to room temperature and stirred for 4 h before being used directly in the next step.
[0352] (2) Synthesis of cyclobutylmethyl 1-(methoxymethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Example 17)
[0353]
[0354] The intermediate 29 (80 mg, 0.342 mmol) was dissolved in ultra-dry DCM (5.0 mL), TEA (143 μL, 1.03 mmol) was added, and the reaction bottle was placed in an ice-water bath. Under Ar protection, the intermediate 32 (1.0 mL, 0.684 mmol) was added and reacted for about 10 min. Saturated NH4Cl (10 mL) was added to quench the reaction, and it was extracted with DCM (10 mL×2). The organic phases were combined, washed with saturated NaCl (10 mL), dried over anhydrous MgSO4, filtered and concentrated, and column chromatography (SiO2, DCM / EA, EA=6-22%) was performed to obtain 30 mg of a white solid with a yield of 33.77% and a melting point of 95-97°C.
[0355] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.67 (s, 1H), 7.30 (s, 1H), 5.51 (t, J = 5.6Hz, 1H), 4.71 (s, 2H), 4.11 (d, J = 6.4Hz, 2H), 3.83–3.67 (m, 4H), 3.42 ( s,3H),2.99(t,J=6.0Hz,2H),2.65(p,J=7.2Hz,1H),2.12–2.04(m,2H),2.00–1.83(m,2H),1.83–1.71(m,2H); HR-MS(ESI):m / z,calcd.For C 19 H 24 O5N[M+H] + 346.1649,Found:346.1663.
[0356] Embodiment 18:
[0357] Synthesis of tert-butyl 1-methyl-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0358]
[0359] Intermediate 24 (612 mg, 1.92 mmol) was dissolved in THF, Ar protected, and methylmagnesium bromide (1.1 mL, 2.31 mmol) in ether (3 M) was added dropwise. The reaction was allowed to react for 2 h in an ice-water bath, and the reaction was stopped. Water was added to quench the reaction, and the reaction was extracted with DCM (20 ml), washed with saturated NH4Cl (20 ml), washed with saturated NaCl (30 ml), dried over anhydrous MgSO4, and filtered. Purification by column chromatography (SiO2, PE / EA EA = 16%) gave 420 mg of a white solid, with a yield of 72.75%, and a melting point of 121-123 °C.
[0360] 1 H NMR (500MHz, CDCl3) δ (ppm) 7.64 (s, 1H), 7.20 (s, 1H), 5.51 (q, J = 6.5Hz, 1H), 4.66 (s, 2H),3.68(t,J=6.0Hz,2H),2.96(t,J=6.0Hz,2H),1.61(d,J=7.0Hz,3H),1.50(s,9H); 13 C NMR(150MHz,DMSO-d6)δ(ppm)170.19,154.69,149.41,142.21,135.45,124.15,123.41,121.70 ,80.28,77.46,45.99(45.35),41.35(40.31),29.95,28.45,20.55; HR-MS(ESI):m / z,calcd.For C 13 H 14 O4N[(M-C4H9)+H] + 248.0917,Found:248.0929.
[0361] Embodiment 19:
[0362] Synthesis of tert-butyl 1-ethyl-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0363]
[0364] Intermediate 24 (592 mg, 1.82 mmol) was dissolved in THF (25 mL), and Ar was protected. Ethyl magnesium bromide (1.05 mL, 3.15 mmol) in ether (3 M) was added dropwise under ice-water bath. After the addition was complete, the mixture was heated to room temperature and reacted for 3 h. The reaction was stopped, quenched with water (10 mL), extracted with DCM (20 mL), and the organic phase was washed with saturated NH4Cl (10 mL), saturated NaCl (10 mL), dried over anhydrous MgSO4, filtered and concentrated. Purified by column chromatography (SiO2, PE / EA, EA=16%), 311 mg of a white solid was obtained, with a yield of 52.95%, and a melting point of 135-137°C.
[0365] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.63 (s, 1H), 7.18 (s, 1H), 5.38 (dd, J1 = 7.2Hz, J2 = 4.4Hz, 1H), 4.65 (s, 2H), 3.67 (t, J = 6.0Hz, 2H), 2.95(t,J=6.0Hz,2H),2.14–2.04(m,1H),1.84–1.75(m,1H),1.48(s,9H),0.98(t,J=9.2Hz,3H); HR-MS(ESI):m / z,calcd.ForC 14 H 16 O4N[(M-C4H9)+H] + 262.1074,Found:262.1062.
[0366] Embodiment 20:
[0367] Synthesis of tert-butyl 1-ethyl-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0368]
[0369] Intermediate 24 (100 mg, 391.41 μmol) was dissolved in THF (5 mL), Ar protected, and propylmagnesium bromide (0.313 mL, 626.26 μmol) in ether (2M) was added, and the reaction was carried out in an ice-water bath for 2 h. The reaction was stopped, quenched with water (10 mL), extracted with DCM (10 mL×2), and the organic phases were combined, washed with saturated NH4Cl (10 mL), washed with saturated NaCl (10 mL), dried over anhydrous MgSO4, filtered and concentrated. Purified by column chromatography (SiO2, PE / EA, EA=20%), 65 mg of a white solid was obtained, with a yield of 57.82%, and a melting point of 93-95°C.
[0370] 1H NMR (400MHz, DMSO-d6) δ (ppm) 7.68 (s, 1H), 7.47 (s, 1H), 5.58 (dd, J1 = 8.0Hz, J2 = 4.0Hz, 1H), 4.61 (s, 2H), 3.56 (t, J = 6.0Hz ,2H),2.93(t,J=6.0Hz,2H),2.03–1.96(m,2H),1.70–1.59(m,1H),1.38(s,9H),1.36–1.20(m,2H),0.92(t,J=7.6Hz,3H); 13 C NMR (150MHz, CDCl3) δ (ppm) 170.40, 154.68, 148.33, 142.06, 135.37, 124.51, 123.40, 121.86, 80.97, 80.27,46.01(45.28),41.38(40.28),36.95,29.95,28.45,18.21,13.80; HR-MS(ESI):m / z,calcd.For C 19 H 26 O4N[M+H] + 332.1856,Found:332.1858.
[0371] Embodiment 21:
[0372] Synthesis of tert-butyl 1-cyclopropyl-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0373]
[0374] Intermediate 24 (125 mg, 391.41 μmol) was dissolved in THF (5 mL), Ar protected, and a THF solution (0.5 M) of cyclopropylmethylmagnesium bromide (1.57 mL, 782.82 μmol) was added. The reaction was reacted in an ice-water bath for 3 h. The reaction was stopped, quenched with water (10 mL), extracted with DCM (20 mL), and the organic phase was washed with saturated NH4Cl (10 mL), saturated NaCl (10 mL), dried over anhydrous MgSO4, filtered and concentrated. Purified by column chromatography (SiO2, PE / EA, EA=16%), 45 mg of a white solid was obtained, with a yield of 34.90%, and a melting point of 166-168°C. 1H NMR (400MHz, DMSO-d6) δ (ppm) 7.65 (s, 1H), 7.46 (s, 1H), 4.97 (d, J = 8.8Hz, 1H), 4.57 (s, 2H), 3. 52(t,J=6.0Hz,2H),2.91(t,J=6.0Hz,2H),1.39(s,9H),1.07–0.93(m,1H),0.69–0.40(m,4H); 13 C NMR (150MHz, CDCl3) δ (ppm) 170.17,154.72,147.90,142.15,135.68,124.54,123.34,122.33,84.95 ,80.31,46.06(45.35),41.41(40.33),29.98,28.48,14.71,2.80,1.94; HR-MS(ESI):m / z,calcd.For C 15 H 16 O4N[(M-C4H9)+H] + 274.1074,Found:274.1088.
[0375] Embodiment 22:
[0376] Synthesis of tert-butyl 3-oxo-1-propyl-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate
[0377]
[0378] Intermediate 24 (100 mg, 313.13 μmol) was dissolved in THF (5 mL), Ar protected, butylmagnesium bromide (0.626 mL, 626.26 μmol) in THF solution (2M) was added, and the reaction was reacted in an ice-water bath for 4 h. The reaction was stopped, and the reaction solution was quenched with water (10 mL), extracted with DCM (20 mL), and the organic layer was washed with saturated NH4Cl (10 mL), saturated NaCl (10 mL), dried over anhydrous MgSO4, and filtered. Purification by column chromatography (SiO2, PE / EA, EA=20%) gave 60 mg of a colorless oil with a yield of 55%. Slurrying with n-hexane gave 25 mg of a white solid with a yield of 32.5%, melting point: 95-97°C.
[0379] 1H NMR (400MHz, DMSO-d6) δ (ppm) 7.63 (s, 1H), 7.43 (s, 1H), 5.53 (dd, J1 = 8.0Hz, J2 = 4.0Hz, 1H), 4.56 (s, 2H), 3.52 (t, J = 6.0Hz, 2H), 2.89 (t, J=5.8Hz,2H),2.03–1.94(m,1H),1.72–1.53(m,1H),1.38(s,9H),1.34–1.21(m,4H),0.82(t,J=6.8Hz,3H); HR-MS(ESI):m / z,calcd.For C 20 H 28 O4N[M+H] + 346.2013,Found:346.2017.
[0380] Pharmacological experiments:
[0381] 1. IC of compounds for inhibition of rat MAO-B / A 50 value
[0382] 1.1 Experimental Grouping
[0383] Negative control group: 100 μL of 200 μg / mL liver tissue fluid and 2 μL DMSO were added to each well of a 96-well all-black fluorescent ELISA plate;
[0384] Positive drug group: 100 μL of liver tissue fluid and 2 μL of positive drug solution of different concentrations were added to each well of the positive drug reaction well;
[0385] Blank control group: 100 μL PB buffer and 2 μL DMSO were added to each well;
[0386] Drug screening group: 100 μL of liver tissue fluid and different concentrations of compounds were added to each well.
[0387] 1.2 Detection of MAOs activity by Amplex Red fluorescence method
[0388] Cover the 96-well plate with a black plastic plate cover and place it in a 37°C incubator for pre-incubation for 30 minutes. Under light-proof conditions, take a 200μL Amplex Red reagent, a 100μL HRP, and a 200μL benzylamine solution, add them to 9.5mL PB buffer and mix well. Wrap the test tube with tin foil and add 98μL Amplex Red reagent / HRP / benzylamine substrate reaction solution to each well under light-proof conditions (for determination of inhibition of MAO-B activity) or add 98μL Amplex Red reagent / HRP / tyramide substrate reaction solution to each well under light-proof conditions (for determination of inhibition of MAO-A activity). Keep the 96-well plate in a 37°C incubator, cover it, and incubate it for 30 minutes in light-proof conditions. Use a fluorescence microplate reader and set the relevant parameters to 560±10nm excitation light and 590±10nm emission light conditions to detect the fluorescence value of each well.
[0389] 1.3 Statistical analysis
[0390] Calculation of compound inhibition rate:
[0391] Negative control group: (average value of positive drug safinamide group - average value of negative control group) / (average value of blank control group - average value of negative control group) × 100%
[0392] Drug screening group: (average value of compound group - average value of negative control group) / (average value of blank control group - average value of negative control group) × 100%
[0393] To calculate the IC of compounds for inhibition of MAO-B / A 50 At least 3 concentrations were selected for each compound, and at least n = 3 for each concentration. IC was fitted using GraphPad Prism 5. 50 .
[0394] The experimental results are shown in Table 1
[0395] Table 1. IC values of compounds for inhibition of MAO-B / MAO-A 50
[0396]
[0397]
[0398] a percentage inhibition at 10μM concentration. b ND=not detected.
Claims
1. A compound as shown in general formula I or a pharmaceutically acceptable salt thereof In Formula I, A is selected from: NH, O; R 1 Selected from: (1) C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched alkyl; (2) Substituted or unsubstituted C3, C4, C5, C6, C7 cycloalkanes, substituted or unsubstituted C3, C4, C5, C6, C7 cycloalkanes substituted with methyl, including but not limited to the following structures: Wherein X is selected from CH 2 , NH, O, S; R 4 A straight chain or branched chain alkyl selected from C1, C2, C3, a straight chain or branched chain alkyl substituted with halogen; the halogen is selected from F, Cl; R 2 , R 3 independently selected from H, C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, nitro-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, (CH 2 )n 1 , CH 2 CH(CH 3 )CH 2 oeLh 1 , (CH 2 )mCHCH 3 oeLh 1 , CH 2 C(CH 3 ) 2 oeLh 1 , CH 2 CH(CH 2 CH 3 ) 1 , (CH 2 ) 2 R 3 , CH 2 CH(CH 3 )CH 2 NRw 2 R 3 , (CH 2 )mCH(CH 3 )NRw 2 R 3 , CH 2 C(CH 3 ) 2 NRw 2 R 3 , CH 2 CH(CH 2 CH 3 )NRw 2 R 3 , The Rw 1 , Rw 2 , Rw 3 Independently selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen substituted C1, C2, C3, C4 straight chain or branched alkyl; n is selected from 0, 1, 2, 3, 4; m is selected from 0, 1, 2; o is selected from 1, 2, 3, 4, 5; X is selected from CH 2 , NH, O.
2. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, It is characterized in that The compound is shown in general formula IA In Formula IA, R 1 Selected from: (1) C1, C2, C3, C4, C5, C6 straight chain or branched chain alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched chain alkyl; (2) Substituted or unsubstituted C3, C4, C5, C6, C7 cyclic alkanes, including but not limited to the following structures: Wherein X is selected from CH 2 , NH, O, S; R 4 Selected from C1, C2, C3 straight chain or branched alkyl, halogen-substituted C1, C2, C3 straight chain or branched alkyl; halogen is selected from F, Cl.
3. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, It is characterized in that The compound is shown in the general formula IB In Formula IB, R 1 Selected from: (1) C1, C2, C3, C4, C5, C6 straight chain or branched chain alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched chain alkyl; (2) Substituted or unsubstituted C3, C4, C5, C6, C7 cyclic alkanes, including but not limited to the following structures: Wherein X is selected from CH 2 , NH, O, S; R 4 A straight chain or branched chain alkyl selected from C1, C2, C3, a straight chain or branched chain alkyl substituted with halogen; the halogen is selected from F, Cl; R 5 selected from C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, nitro-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, (CH 2 )n 1 , CH 2 CH(CH 3 )CH 2 oeLh 1 , (CH 2 )mCHCH 3 oeLh 1 , CH 2 C(CH 3 ) 2 oeLh 1 , CH 2 CH(CH 2 CH 3 ) 1 , (CH 2 ) 2 R 3 , CH 2 CH(CH 3 )CH 2 NRw 2 R 3 , (CH 2 )mCH(CH 3 )NRw 2 R 3 , CH 2 C(CH 3 ) 2 NRw 2 R 3 , CH 2 CH(CH 2 CH 3 )NRw 2 R 3 , The Rw 1 , Rw 2 , Rw 3 Independently selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen substituted C1, C2, C3, C4 straight chain or branched alkyl; n is selected from 0, 1, 2, 3, 4; m is selected from 0, 1, 2; o is selected from 1, 2, 3, 4, 5; X is selected from CH 2 , NH, O.
4. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, It is characterized in that The compound is shown in the general formula IC In the IC, R 1 Selected from: (1) C1, C2, C3, C4, C5, C6 straight chain or branched chain alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched chain alkyl; (2) Substituted or unsubstituted C3, C4, C5, C6, C7 cyclic alkanes, including but not limited to the following structures: Wherein X is selected from CH 2 , NH, O, S; R 4 A straight chain or branched chain alkyl selected from C1, C2, C3, a straight chain or branched chain alkyl substituted with halogen; the halogen is selected from F, Cl; R 6 selected from C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, nitro-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, (CH 2 )n 1 , CH 2 CH(CH 3 )CH 2 oeLh 1 , (CH 2 )mCHCH 3 oeLh 1 , CH 2 C(CH 3 ) 2 oeLh 1 , CH 2 CH(CH 2 CH 3 ) 1 , (CH 2 ) 2 R 3 , CH 2 CH(CH 3 )CH 2 NRw 2 R 3 , (CH 2 )mCH(CH 3 )NRw 2 R 3 , CH 2 C(CH 3 ) 2 NRw 2 R 3 , CH 2 CH(CH 2 CH 3 )NRw 2 R 3 , The Rw 1 , Rw 2 , Rw 3 Independently selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen substituted C1, C2, C3, C4 straight chain or branched alkyl; n is selected from 0, 1, 2, 3, 4; m is selected from 0, 1, 2; o is selected from 1, 2, 3, 4, 5; X is selected from CH 2 , NH, O.
5. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, It is characterized in that The compound is selected from the following group:
6. A compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof, It is characterized in that The pharmaceutically acceptable salts of the compounds are selected from salts formed by combining with inorganic acids, organic acids, alkali metal ions, alkaline earth metal ions or organic bases that can provide physiologically acceptable cations and ammonium salts.
7. A compound according to claim 6 or a pharmaceutically acceptable salt thereof, It is characterized in that The inorganic acid is selected from hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid; the organic acid is selected from methanesulfonic acid, p-toluenesulfonic acid, trifluoroacetic acid, citric acid, maleic acid, tartaric acid, fumaric acid, citric acid or lactic acid; the alkali metal ion is selected from lithium ion, sodium ion, potassium ion; the alkaline earth metal ion is selected from calcium ion and magnesium ion; the organic base capable of providing physiologically acceptable cations is selected from methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris(2-hydroxyethyl)amine.
8. A process for preparing a compound according to any one of claims 1 to 7, It is characterized in that The steps include: According to the 3-substituent (R 2 , R 3 ), and the compound represented by general formula I was synthesized by the synthesis method of Scheme 1-5; Using 1,2,3,4-tetrahydroisoquinolin-6-ol 1 as the starting material, a trifluoroacetyl protecting group was introduced at the 1-position of 1,2,3,4-tetrahydroisoquinolin-6-ol through an acylation reaction to obtain intermediate 2; Intermediate 2 is acylated with trifluoromethanesulfonyl chloride to prepare intermediate 3; Intermediate 3 is reacted with N-formyl saccharin through coupling reaction to prepare intermediate 4; Intermediate 4 undergoes bromination reaction with NBS to obtain intermediate 5; Intermediate 5 was treated with potassium carbonate aqueous solution to remove the trifluoroacetyl group to obtain a non-substituted compound on the N side; on this basis, an acylation reaction was used to introduce a Boc substituent to obtain intermediate 6; Intermediate 6 is reduced to give intermediate 7; Intermediate 7 undergoes carbonyl insertion coupling reaction to obtain a compound of formula IA; If the substituted N atom is a Boc group, use trifluoroacetic acid or hydrogen chloride in 1,4-dioxane to remove Boc to obtain a compound without substitution on N; on this basis, introduce the substituent R through substitution reaction 1 , to obtain the compound represented by the general formula IA; Using 1,2,3,4-tetrahydroisoquinolin-6-ol 1 as the starting material, a Boc protecting group was introduced at the 1-position of 1,2,3,4-tetrahydroisoquinolin-6-ol through an acylation reaction to obtain intermediate 8; Intermediate 8 undergoes Friedel-Crafts acylation with paraformaldehyde to prepare intermediate 9; Intermediate 9 is acylated with trifluoromethanesulfonyl chloride to prepare intermediate 10; Intermediate 10 undergoes Pinnick oxidation reaction to obtain intermediate 11; Intermediate 11 undergoes esterification reaction with methyl iodide to obtain intermediate 12; Intermediate 12 undergoes coupling reaction with potassium vinyl trifluoroborate to obtain intermediate 13; Intermediate 13 is subjected to oxidation reaction to obtain intermediate 14; Intermediate 14 was reacted with an alkyl Grignard reagent to introduce R 5 , to obtain the compound represented by the general formula IB; If the substituted N atom is a Boc group, a 1,4-dioxane solution of trifluoroacetic acid or hydrogen chloride is used to remove the Boc group, and on this basis, a substituent is introduced through a substitution reaction to obtain a compound represented by the general formula IB; Intermediate 13 undergoes hydrolysis to obtain intermediate 15; Intermediate 15 is subjected to oxidation reaction to obtain intermediate 16; Intermediate 16 undergoes substitution reaction with an alkyl halide to give intermediate 17; Intermediate 17 is treated with a 1,4-dioxane solution of trifluoroacetic acid or hydrogen chloride to remove Boc, and a substituent is introduced through a substitution reaction to obtain a compound of the general formula IB; Intermediate 10 reacts with substituted acetylene compounds via Sonogashira coupling to prepare key intermediate 18; Intermediate 18 undergoes Pinnick oxidation reaction to obtain intermediate 19; Intermediate 19 undergoes hydrogenation reduction reaction to obtain intermediate 20; Intermediate 20 uses trifluoroacetic acid or hydrogen chloride in 1,4-dioxane solution to remove Boc, and introduces a substituent through a substitution reaction to obtain a compound represented by the general formula IB; Intermediate 10 was reacted with triisopropylsilyl acetylene via Sonogashira coupling to prepare key intermediate 21; The silicon protecting group of intermediate 21 was removed by tetrabutylammonium fluoride to obtain intermediate 22; Intermediate 22 undergoes Pinnick oxidation reaction to obtain intermediate 23; Intermediate 23 undergoes hydrolysis to obtain intermediate 24; Intermediate 24 undergoes esterification with methyl iodide to give intermediate 25; Intermediate 25 undergoes a nucleophilic addition reaction with an alkyl Grignard reagent or DAST to obtain a compound represented by the general formula IC; if the substituted N atom is a Boc group, a 1,4-dioxane solution of trifluoroacetic acid or hydrogen chloride is used to remove the Boc group to obtain a compound without substitution on N; on this basis, a substituent is introduced through a substitution reaction to obtain a compound represented by the general formula IC; The R 1 , R 5 , R 6 Same as the definition in claims 1 to 7, R 8 selected from H, C1, C2, C3, C4, C5 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4, C5 straight chain or branched alkyl, nitro-substituted C1, C2, C3 straight chain or branched alkyl, (CH 2 )n 1 , CH 2 CH(CH 3 )CH 2 oeLh 1 , (CH 2 )mCHCH 3 oeLh 1 , CH 2 C(CH 3 ) 2 oeLh 1 , CH 2 CH(CH 2 CH 3 ) 1 , (CH 2 ) 2 R 3 , CH 2 CH(CH 3 )CH 2 NRw 2 R 3 , (CH 2 )mCH(CH 3 )NRw 2 R 3 , CH 2 C(CH 3 ) 2 NRw 2 R 3 , CH 2 CH(CH 2 CH 3 )NRw 2 R 3 , The Rw 1 , Rw 2 , Rw 3 Independently selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen substituted C1, C2, C3, C4 straight chain or branched alkyl; n is selected from 1, 2, 3; m is selected from 1; o is selected from 1, 2, 3, 4, 5; X is selected from CH 2 ,NH,O;R 7 Selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl.
9. A pharmaceutical composition, It is characterized in that The invention comprises an effective dose of the compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof and a pharmacologically acceptable carrier.
10. Use of the compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof in the preparation of an MAO-B and / or MAO-A inhibitor.
11. Use of a compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing and / or treating diseases associated with MAO-B and / or MAO-A.
12. The use according to claim 11, It is characterized in that The disease associated with MAO-B and / or MAO-A is selected from psychiatric and nervous system diseases, metabolic diseases, cardiovascular system diseases or cancer.
13. The use according to claim 12, It is characterized in that The mental and nervous system diseases include Parkinson's disease, senile dementia, Alzheimer's disease, depression, and anxiety.
